

European Pharmacopoeia

Background

The pharmaceutical legislation in the European Union makes the specific and general monographs of the European Pharmacopoeia (EP) legally binding.

The EP Commission is in charge of judging the suitability of monographs developed by the groups of experts. Prior to release, a new monograph must be adopted by the EP Commission, and is then published in the compendium or its supplements.

To support the monographs of the European Pharmacopoeia, a collection of reference substances has been made available which includes:

1. Current, official, European Pharmacopoeia Chemical Reference Substances (EP CRS) and Biological Reference Preparations (BRP)
2. Reference Spectra
3. Other reference preparations, including Enzymes and Substrates from the International Commission on Pharmaceutical Enzymes and Certified Viscosity Standards from Van Swinden Laboratories.
4. With supplement 4.3, the revised EP general method 2.2.6 replaces CRS reference liquids with certified reference materials available from suppliers of chemical reagents or materials certified for metrology. Ten liquid CRMs, certified by the Physical Chemistry Division of the Central Office of Measures (GUM), Warsaw in Poland, cover the wide range of refractive index from 1,333 (water) to 1,657 (1-bromonaphthalene). More detailed information is given in the chapter "Dyes and refractive index CRMs" of this catalogue.
5. European Pharmacopoeia Reagents.

New lists of EP CRS/BRP are published three times a year. The EP CRS/BRP in this catalogue comprise the product range of the EP as of May 2010. Additional actual information will be included in our newsletters published subsequently.

Relationship with other pharmacopoeias in Europe

Any reference substance, spectra or preparation required for a new EP monograph, is made available as soon as the monograph comes into force.

Many of the member countries of the European Pharmacopoeia Commission have adopted the EP in full, and their monographs require only EP CRS/BRP. When an EP monograph is adopted by the pharmacopoeia of a member state of the Council of Europe then any reference material that may have been available from a national pharmacopoeia, e.g. BP or PF, will usually be discontinued in favour of the EP reference substance. However, a number of member countries of the EP Commission maintain national pharmacopoeial monographs, especially for finished dosage forms, which require the use of separate reference substances.

A separate chapter in this catalogue includes lists of the reference substances produced for the British, French, Swiss and International pharmacopoeia monographs. The International Pharmacopoeia (IP) reference substances are described in the section referring to the WHO (World Health Organization).

Production and certification

European Pharmacopoeia reference substances and preparations are selected and verified by the EP laboratories as being suitable for the use as prescribed in the relevant monograph of the European Pharmacopoeia.

Since CRS and BRP are officially certified by the European Pharmacopoeia Commission, it should be noted that neither certificates of analysis nor data not relevant to the use of the products as defined by the EP monograph are provided with the reference product or substance.

Controlled Substances

The EP list contains substances subject to **Controlled Substance** regulations schedules. Special ordering procedures apply, so please contact LGC Standards for details and costs.

Storage, shelf life and expiry dates

European Pharmacopoeia CRS/BRP are subject to regular inspection and repeated analysis by EP scientific staff. Each EP CRS/BRP is, on receipt by the customer, fit for the intended use.

No expiry date is indicated on the reference materials because the products or substances comply with the requirements of the corresponding monograph and are monitored regularly. When batches are to be changed, the EP CRS catalogue shows the date on which the lot will no longer be official.

In specific cases for reasons related to filling or labeling, sub-batches are obtained from the same batch of bulk material. However, all the necessary precautions are taken in order to guarantee that the quality and specifications of the sub-batches do not differ from one to another. The EP changed the labeling structure of the sub-batches recently. Sub-batches are now labeled for example as 2.1, 2.2, 2.3 instead of 2a, 2b, 2c.

The EP is also currently over-labelling all its reference standards vials with a secondary label. This new secondary label is useful for customs purposes as it can be peeled off. It can also be stuck onto your laboratory book to prove the use of the reference standard. All the required information to perform the tests described in the European Pharmacopoeia monographs are stated on the primary label.

EP recommends only sufficient material should be purchased for immediate use and that unopened vials should be stored in the dark unless otherwise stated. Whilst most EP CRS/BRP can be shipped at ambient temperature, certain items have to be maintained at controlled temperatures at all times and are subject to special shipping charges and storage conditions (details are available on request).

Where no drying conditions are stated, the substance is to be used as received.

Once opened, EP and LGC Standards can no longer guarantee the stability of the material and any of the CRS/BRP not used should be disposed of and not kept for future use.

Validation of secondary standards

All secondary in-house working standards have to be validated against the CURRENT batch of the EP CRS/BRP, so we advise you to check that you have current batch numbers.

As your supplier of choice, LGC Standards can provide lists of current batch numbers of EP CRS/BRP, so call us to receive these today. We can provide the same service for USP reference standards, which are listed in the USP chapter of this catalogue. Please take this opportunity to subscribe to this free service by contacting your local LGC Standards office.

Proper use

EP discontinued their use code number system as of January 2006.

For information on the use of the substances please refer to the corresponding monographs or contact your local LGC Standards office.

Reference substances from EP are intended to be used in connection with the respective monographs, and for no other purpose. If used for any other purpose the responsibility of such use lies completely with the user.

Opening

For reference substances and preparations supplied in sealed glass ampoules the following technique is suitable for opening the ampoule: tap gently to collect the material at the lower end, score the ampoule with a file, heat a glass rod to white heat and apply firmly to the file mark. If the glass does not crack, deepen and extend the file mark, and repeat the process. **Eye and hand protection MUST be used.**

Many reference substances are supplied as lyophilised material in a septum vial. No attempt should be made to open the vial and weigh out the powder. It is important to strictly follow the monograph instructions, reconstitute the material in a buffer solvent and handle the resultant solution volumetrically.

Toxicity

The potential toxicity of certain reference substances is such that special precautions should be taken to avoid contact.

Such substances should be manipulated in a glove box. If this is not possible, gloves, eye protection and a mask should be worn.

Following the guidelines suggested by the EP does not replace the need to carry out a full hazard assessment.

Biological and blood products should be regarded as potentially hazardous to health and therefore used and disposed of according to established laboratory safety procedures.

| Code | Product | Unit |
|-----------------------|---|-----------|
| EPY0000055 | Acamprosate calcium - Reference Spectrum | unit |
| EPY0000116 | Acamprosate impurity A 3-aminopropane-1-sulphonic acid | 50 mg |
| EPY0000500 | Acarbose | 94.7 mg |
| EPY0000354 | Acarbose for identification | 10 mg |
| EPY0000427 | Acarbose for peak identification | 40 mg |
| EPA0040000 | Acebutolol hydrochloride | 50 mg |
| EPY0000359 | Acebutolol impurity B N-[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]acetamide (diacetolol) | 10 mg |
| EPY0000127 | Acebutolol impurity C N-(3-acetyl-4-hydroxyphenyl)butanamide | 20 mg |
| EPY0000128 | Acebutolol impurity I N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl]butanamide | 0.004 mg |
| EPY0000056 | Aceclofenac - Reference Spectrum | unit |
| EPY0001094 | Aceclofenac for peak identification | 10 mg |
| EPY0000085 | Aceclofenac impurity F benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate | 20 mg |
| EPY0000086 | Aceclofenac impurity H [[[[[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetyl]oxy]acetyl]oxy]acetic acid | 10 mg |
| EPY0000810 | Acemetacin | 100 mg |
| EPY0000811 | Acemetacin impurity A 4-chlorobenzoic acid | 10 mg |
| EPY0000842 | Acemetacin impurity mixture | 0.06 mg |
| EPA0070000 | Acesulfame potassium | 50 mg |
| EPA0070020 | Acesulfame potassium impurity B 5-chloro-6-methyl-1,2,3-oxathiazin-4(3H)-one 2,2-dioxide | 10 mg |
| EPA0100000 | Acetazolamide | 100 mg |
| EPY0001084 | Acetazolamide for system suitability | 0.0068 mg |
| EPY0000002 | Acetylcholine chloride | 50 mg |
| EPA0150000 | Acetylcysteine | 50 mg |
| EPA0152000 | Acetylcysteine impurity C N,N'-diacetyl-L-cystine | 10 mg |
| EPA0153000 | Acetylcysteine impurity D N,S-diacetyl-L-cysteine | 10 mg |
| EPY0000565 | β-Acetyldigoxin | 50 mg |
| EPY0000642 | β-Acetyldigoxin for peak identification | 10 mg |
| EPA0200000 | Acetylsalicylic acid | 100 mg |
| EPA0208000 | N-Acetyltryptophan | 125 mg |
| EPA0202000 | N-Acetyltyrosine | 200 mg |
| EPY0000693 | Acholeplasma laidlawii BRP | 1 mL |
| EPA0220000 | Aciclovir | 75 mg |
| EPA0221000 | Aciclovir impurity A 2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl acetate | 15 mg |
| EPA0225000 | Acitretin | 100 mg |
| New EPY0001121 | Adapalene | 100 mg |
| New EPY0001120 | Adapalene impurity C 1-[2-(methyloxy)phenyl]tricyclo[3.3.1.1]decane | 5 mg |
| New EPY0001119 | Adapalene for peak identification | 2.022 mg |
| EPA0230000 | Adenine | 50 mg |
| EPA0230200 | Adenosine | 50 mg |
| EPY0000110 | Adipic acid | 50 mg |
| EPY0000882 | Adrenaline | 5 mg |
| EPY0000883 | Adrenaline with impurity F | 10 mg |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|--|----------|
| EPA0300000 | Adrenaline tartrate | 100 mg |
| EPY0000740 | Adrenaline impurity mixture | 0.005 mg |
| EPY0000707 | Adrenaline tartrate with impurity A | 15 mg |
| EPY0000728 | Agnus castus fruit standardised dry extract | 200 mg |
| EPA0325000 | Alanine | 50 mg |
| EPA0325100 | Albendazole | 50 mg |
| EPA0325200 | Alcuronium chloride | 50 mg |
| EPA0325450 | Alfacalcidol | 5 mg |
| EPA0325451 | Alfacalcidol - Reference Spectrum | unit |
| EPA1225000 | Alfadex | 150 mg |
| EPA0325500 | Alfentanil hydrochloride - Reference Spectrum | unit |
| EPA0325800 | Alfuzosin hydrochloride | 10 mg |
| EPY0000832 | Alfuzosin for system suitability | 10 mg |
| EPA0349000 | Allantoin | 60 mg |
| EPA0350000 | Allopurinol | 50 mg |
| EPA0350010 | Allopurinol impurity A 5-amino-1H-pyrazole-4-carboxamide | 10 mg |
| EPA0350020 | Allopurinol impurity B 5-formylamino-1H-pyrazole-4-carboxamide | 10 mg |
| EPA0350030 | Allopurinol impurity C N-(4H-1,2,4-triazol-4-yl)1H-pyrazole-4-carboxamide | 10 mg |
| EPA0350040 | Allopurinol impurity D ethyl 5-amino-1H-pyrazole-4-carboxylate | 10 mg |
| EPA0350050 | Allopurinol impurity E ethyl 5-(formylamino)-1H-pyrazole-4-carboxylate | 20 mg |
| EPA0351000 | Allylstrychnine bromide | 10 mg |
| EPY0000235 | Almagate | 25 mg |
| EPY0000255 | Almagate - Reference Spectrum | unit |
| EPA0357000 | Alprazolam Controlled Substance | 100 mg |
| EPA0360000 | Alprenolol hydrochloride | 100 mg |
| EPY0000054 | Alprostadil | 50 mg |
| EPY0000606 | Altizide | 150 mg |
| EPY0000843 | Altizide impurity B 3-[(2,2-dimethoxyethyl)sulphonyl]prop-1-ene | 15 mg |
| EPY0000687 | Alverine citrate | 5 mg |
| EPY0000595 | Alverine for peak identification | 0.125 mg |
| EPY0000607 | Alverine impurity D N-(3-cyclohexylpropyl)-N-ethyl-3-phenylpropan-1-amine | 10 mg |
| EPA0363000 | Amantadine hydrochloride | 100 mg |
| EPA0363700 | Ambroxol hydrochloride | 125 mg |
| EPA0900000 | Amfetamine sulphate - Reference Spectrum | unit |
| EPA0365000 | Amidotrizoic acid dihydrate | 100 mg |
| EPA0368000 | Amikacin | 200 mg |
| EPA0365900 | Amikacin sulphate | 200 mg |
| New EPY0001117 | Amikacin for system suitability | 20 mg |
| EPA0370000 | Amiloride hydrochloride | 100 mg |
| EPY0000020 | Amiloride impurity A methyl-3,5-diamino-6-chloropyrazine-2-carboxylate | 10 mg |
| EPY0000173 | 4-Aminobenzoic acid | 60 mg |
| EPA0420000 | Aminocaproic acid | 50 mg |
| EPA0460000 | 7-Aminodesacetoxycephalosporanic acid | 20 mg |
| EPA0496000 | Aminoglutethimide | 125 mg |

| Code | Product | Unit |
|-----------------------|--|--------|
| EPA0496005 | Aminoglutethimide impurity A (3RS)-3-(3-aminophenyl)-3-ethylpiperidine-2,6-dione; (3-aminoglutethimide) | 20 mg |
| EPA0496020 | Aminoglutethimide impurity D 3,3'-[diazenediyl]di(4,1-phenylene)]bis(3-ethylpiperidine-2,6-dione) (azoglutethimide) | 10 mg |
| EPA0575000 | Amiodarone hydrochloride | 100 mg |
| EPY0000129 | Amiodarone impurity D (2-butyl-benzofuran-3-yl)-(4-hydroxy-3,5-diiodophenyl)methanone | 20 mg |
| EPY0000130 | Amiodarone impurity E (2-butylbenzofuran-3-yl)(4-hydroxyphenyl)methanone | 20 mg |
| EPA0590000 | Amisulpride | 50 mg |
| EPA0590004 | Amisulpride impurity B 4-amino-N-[[[(2RS)-1-ethylpyrrolidin-2-yl] methyl]-5-(ethylsulphonyl)-2-hydroxybenzamine | 10 mg |
| EPY0000563 | Amitriptyline hydrochloride | 10 mg |
| EPY0000049 | Amlodipine besilate | 150 mg |
| New EPY0001067 | Amlodipine for peak identification | 10 mg |
| New EPY0001068 | Amlodipine impurity A 3-ethyl 5-methyl (4RS)-4-(2-chlorophenyl)-2-[[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]methyl]-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate | 10 mg |
| New EPY0001069 | Amlodipine impurity B 3-ethyl 5-methyl (4RS)-4-(2-chlorophenyl)-6-methyl-2-[[2-[[2-(methylcarbamoyl)benzoyl]amino]ethoxy]methyl]-1,4-dihydropyridine-3,5-dicarboxylate | 10 mg |
| New EPY0001070 | Amlodipine impurity G dimethyl 4-(2-chlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate | 10 mg |
| EPY0000302 | Ammonio methacrylate copolymer (type A) - Reference Spectrum | unit |
| EPY0000303 | Ammonio methacrylate copolymer (type B) - Reference Spectrum | unit |
| EPA0650000 | Amobarbital Controlled Substance | 500 mg |
| EPA0700000 | Amobarbital sodium Controlled Substance | 500 mg |
| EPA0800000 | Amoxicillin trihydrate | 100 mg |
| EPY0000005 | Amphotericin B | 100 mg |
| EPY0001014 | Amphotericin B for peak identification | 10 mg |
| EPA1000000 | Ampicillin (anhydrous) | 250 mg |
| EPA1100000 | Ampicillin trihydrate | 150 mg |
| EPA1200000 | Anhydrotetracycline hydrochloride | 15 mg |
| EPA1210000 | Antazoline hydrochloride | 50 mg |
| EPY0000172 | Apomorphine hydrochloride - Reference Spectrum | unit |
| EPA1220000 | Alpha-apo-oxytetracycline | 20 mg |
| EPA1230000 | Beta-apo-oxytetracycline | 20 mg |
| EPA1250000 | Aprotinin solution BRP | 0.5 mL |
| New EPY0001154 | Aprotinin for system suitability | 2.7 mg |
| EPA1269000 | L-Arabinitol | 10 mg |
| EPY0000806 | Arbutin | 100 mg |
| EPA1270000 | Arginine | 50 mg |
| EPY0000304 | Arginine aspartate | 20 mg |
| EPA1271000 | Arginine hydrochloride | 50 mg |
| EPY0000079 | Articaine hydrochloride | 100 mg |
| EPY0000080 | Articaine impurity A methyl 3-[[2-(propylamino)acetyl]amino]-4-methylthiophene-2-carboxylate | 15 mg |
| EPY0000081 | Articaine impurity E methyl 4-methyl-3-[[[(2RS)-2-[(1-methylethyl)amino]propanoyl] amino]thiophene-2-carboxylate | 10 mg |
| EPA1300000 | Ascorbic acid (Vitamin C) | 100 mg |
| EPY0001024 | Ascorbic acid impurity C D-sorbosonic acid | 20 mg |

European Pharmacopoeia

| | Code | Product | Unit |
|------------|------------|--|----------|
| New | EPY0001170 | Ascorbic acid impurity D Methyl D-sorbosonate | 10 mg |
| | EPY0000800 | Ascorbyl palmitate | 10 mg |
| | EPY0000305 | Asparagine monohydrate | 60 mg |
| | EPA1320000 | Aspartame | 40 mg |
| | EPA1321000 | Aspartame impurity A 2-(5-benzyl-3,6-dioxopiperazin-2-yl)acetic acid (diketopiperazine) | 10 mg |
| | EPA1330000 | Aspartic acid | 50 mg |
| | EPA1335000 | Astemizole | 150 mg |
| | EPA1340000 | Atenolol | 100 mg |
| | EPY0001089 | Atenolol for system suitability | 5 mg |
| | EPY0000424 | Atracurium besilate | 120 mg |
| | EPY0000503 | Atracurium for impurity F identification | 5 mg |
| | EPY0000504 | Atracurium for peak identification | 5 mg |
| | EPY0000878 | Atropine | 30 mg |
| | EPY0000845 | Atropine for peak identification | 0.25 mg |
| | EPY0000816 | Atropine impurity B (1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl (2RS)-3-hydroxy-2-phenylpropanoate (noratropine) | 10 mg |
| | EPA1400000 | Atropine sulphate | 50 mg |
| | EPY0000029 | Azaperone | 50 mg |
| | EPA1500000 | Azathioprine | 100 mg |
| | EPY0001240 | Azathioprine impurity A 1-methyl-4-nitro-1H-imidazol-5-amine | 10 mg |
| New | EPY0001246 | Azathioprine impurity G 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purin-2-amine (thiamiprine) | 5 mg |
| | EPY0000326 | Azelastine hydrochloride | 25 mg |
| | EPY0000327 | Azelastine impurity B 1-benzoyl-2-[(4RS)-1-methylhexahydro-1H-azepin-4-yl]diazane | 5 mg |
| | EPY0000328 | Azelastine impurity D 4-(4-chlorobenzyl)phthalazin-1(2H)-one | 5 mg |
| | EPY0000329 | Azelastine impurity E 3-(4-chlorobenzilidene)isobenzofuran-1(3H)-one | 5 mg |
| | EPY0000306 | Azithromycin | 200 mg |
| | EPY0000637 | Azithromycin for peak identification | 15 mg |
| | EPY0000641 | Azithromycin for system suitability | 0.05 mg |
| | EPY0000307 | Azithromycin impurity A 6-demethylazithromycin | 10 mg |
| | EPY0000285 | B19 virus DNA for NAT testing BRP | 150 mg |
| | EPB0070000 | Bacampicillin hydrochloride | 120 mg |
| | EPB0100000 | Bacitracin zinc | 150 mg |
| | EPB0200000 | Baclofen | 50 mg |
| | EPB0200050 | Baclofen impurity A (RS)-4-amino-3-(4-chlorophenyl)butyric acid lactam | 50 mg |
| | EPB0250000 | Bambuterol hydrochloride | 100 mg |
| | EPB0300000 | Barbital Controlled Substance | 500 mg |
| | EPY0000295 | Basic butylated methacrylate copolymer - Reference Spectrum | unit |
| | EPB0305000 | Beclometasone dipropionate anhydrous | 150 mg |
| | EPY0000351 | Beclometasone dipropionate monohydrate | 10 mg |
| | EPY0000352 | Beclometasone dipropionate for system suitability | 10 mg |
| | EPY0000469 | Beclometasone dipropionate for peak identification | 10 mg |
| | EPY0001073 | Beclometasone dipropionate impurities F and N | 0.052 mg |
| | EPY0001025 | Benazepril hydrochloride | 160 mg |
| | EPY0001038 | Benazepril for system suitability | 0.016 mg |

| Code | Product | Unit |
|-----------------------|---|----------|
| EPY0001026 | Benazepril impurity A [(3R)-3-[[[(1R)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid | 10 mg |
| EPB0400000 | Bendroflumethiazide | 100 mg |
| EPY0000564 | Bendroflumethiazide impurity A 4-amino-6-(trifluoromethyl)benzene-1,3-disulphonamide | 5 mg |
| EPY0000044 | Benfluorex hydrochloride | 50 mg |
| EPY0000043 | Benfluorex hydrochloride for system suitability | 360 mg |
| EPB0470000 | Benperidol | 100 mg |
| EPB0477000 | Benserazide hydrochloride | 50 mg |
| EPB0477010 | Benserazide impurity A (RS)-2-amino-3-hydroxypropanohydrazide | 20 mg |
| EPY0001071 | Benserazide impurity C (2RS)-2-amino-3-hydroxy-2'-[[1EZ)-(2,3,4-trihydroxybenzylidene)]propanohydrazide | 10 mg |
| EPY0001079 | Benserazide for peak identification | 10 mg |
| EPY0001064 | Benzaldehyde | 150 mg |
| EPY0001060 | Benzalkonium chloride for system suitability | 20 mg |
| EPB0490000 | Benzarone | 10 mg |
| EPB0500000 | Benzathine benzylpenicillin | 125 mg |
| EPY0000775 | Benzbromarone | 10 mg |
| EPB0550000 | Benzethonium chloride | 100 mg |
| EPB0600000 | Benzocaine | 50 mg |
| EPY0000647 | Benzophenone | 40 mg |
| EPY0000167 | Benzyl alcohol | 50 mg |
| EPB0670000 | Benzyl benzoate - Reference Spectrum | unit |
| EPB0680000 | S-Benzylmercaptoacetyltriglycin | 10 mg |
| EPB0700000 | Benzylpenicillin potassium | 50 mg |
| EPB0900000 | Benzylpenicillin sodium | 200 mg |
| New EPY0001149 | Berberine chloride | 20 mg |
| EPB0950000 | Betadex | 200 mg |
| EPY0000391 | Betahistine dihydrochloride | 50 mg |
| EPB0990000 | Betahistine mesilate | 100 mg |
| EPB1000000 | Betamethasone | 75 mg |
| EPB1030000 | Betamethasone acetate | 100 mg |
| EPB1040000 | Betamethasone dipropionate | 100 mg |
| EPB1045000 | Betamethasone sodium phosphate | 100 mg |
| EPB1054000 | Betamethasone-17-valerate | 100 mg |
| EPB1055000 | Betamethasone-21-valerate | 15 mg |
| EPY0001027 | Betamethasone for system suitability | 25 mg |
| EPY0001065 | Betamethasone valerate impurity mixture | 0.018 mg |
| EPB1103000 | Betaxolol hydrochloride | 60 mg |
| EPB1103100 | Betaxolol impurity A (RS)-3-(4-ethylphenoxy)-1-[[1-methylethyl]-amido]propan-2-ol | 10 mg |
| EPB1115000 | Bezafibrate | 100 mg |
| EPY0001078 | Bicisate labelling kit | 1024 mg |
| EPB1110000 | Bifonazole | 100 mg |
| EPB1110004 | Bifonazole impurity B 4-[(RS)-(biphenyl-4-yl)phenylmethyl]-1H-imidazole trifluoroacetate | 10 mg |
| EPY0001059 | Bilberry dry extract | 250 mg |
| EPB1116000 | Biotin (Vitamin H) | 50 mg |
| EPB1120000 | Biperiden hydrochloride | 60 mg |
| EPB1121000 | Biperiden impurity A (1RS)-1-[(1SR,2SR,4SR)-bicyclo[2.2.1]hept-5-en-2-yl]-1-phenyl-3-(piperidin-1-yl)propan-1-ol (endo form) | 20 mg |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|--|--------|
| EPB1130000 | 1,3-bis(2-acetyl-3-hydroxyphenoxy)-2-propanol | 50 mg |
| EPB1140000 | Bisacodyl | 50 mg |
| EPY0000608 | Bisacodyl for peak identification | 10 mg |
| EPY0000694 | Bisacodyl for system suitability | 5 mg |
| EPY0000812 | Bisoprolol fumarate | 50 mg |
| EPY0000877 | Bisoprolol for system suitability method A | 1 mg |
| EPY0000813 | Bisoprolol for system suitability method B | 1 mg |
| EPB1141000 | Bleomycin sulphate | 7 mg |
| EPY0000434 | Boldine | 30 mg |
| EPB1142000 | Bordetella pertussis mouse antiserum BRP | 0.5 mg |
| EPB1143000 | Bromazepam Controlled Substance | 60 mg |
| EPY0000645 | Bromazepam for system suitability Controlled Substance | 10 mg |
| EPB1145000 | Bromhexine hydrochloride | 100 mg |
| EPY0000200 | Bromhexine impurity C N-(2-aminobenzyl)-N-methylcyclohexanamine | 10 mg |
| EPB1150000 | Bromocriptine mesilate | 30 mg |
| EPY0000677 | Bromocriptine mesilate for system suitability | 5 mg |
| EPB1152000 | Bromperidol | 100 mg |
| EPB1152050 | Bromperidol decanoate | 60 mg |
| EPB1153000 | Brompheniramine maleate | 100 mg |
| EPY0000468 | Brotizolam Controlled Substance | 10 mg |
| EPY0000470 | Brotizolam impurity B 2-bromo-4-(2-chlorophenyl)-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine (demethylbrotizolam) | 10 mg |
| EPB1155000 | Brucella melitensis Rev. 1 strain BRP | 1 mL |
| EPB1157300 | Budesonide | 110 mg |
| New EPY0001148 | Budesonide for system suitability | 10 mg |
| EPB1156000 | Bufexamac | 100 mg |
| EPB1157400 | Buflomedil hydrochloride | 100 mg |
| EPB1157410 | Buflomedil impurity B 4-(pyrrolidin-1-yl)-1-(4-hydroxy-2,6-dimethoxyphenyl)butan-1-one | 20 mg |
| EPB1158000 | Bumetanide | 150 mg |
| EPY0000309 | Bumetanide impurity A 3-nitro-4-phenoxy-5-sulphamoylbenzoic acid | 5 mg |
| EPY0000310 | Bumetanide impurity B 3-amino-4-phenoxy-5-sulphamoylbenzoic acid | 5 mg |
| EPB1160000 | Bupivacaine hydrochloride | 100 mg |
| EPY0000088 | Bupivacaine impurity B (2RS)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide | 20 mg |
| EPY0000089 | Bupivacaine impurity E 6-(butylamino)-N-(2,6-dimethylphenyl)hexanamide | 20 mg |
| EPY0001108 | Buprenorphine Controlled Substance | 10 mg |
| EPY0001109 | Buprenorphine hydrochloride Controlled Substance | 10 mg |
| New EPY0001122 | Buprenorphine for system suitability Controlled Substance | 10 mg |
| EPB1168000 | Buserelin | 2 mg |
| EPB1168020 | D-His-Buserelin | 0.5 mg |
| EPY0000131 | Buspirone hydrochloride | 5 mg |
| EPY0000471 | Buspirone for system suitability | 2 mg |
| EPB1170000 | Busulfan | 50 mg |
| EPB1217000 | Butyl parahydroxybenzoate | 100 mg |
| EPB1212000 | Butylhydroxyanisole | 50 mg |
| EPB1215000 | Butylhydroxytoluene Plastic additive 07 | 50 mg |
| EPY0000472 | Cabergoline | 100 mg |

| Code | Product | Unit |
|-----------------------|---|-----------|
| EPC0100000 | Caffeine | 70 mg |
| EPY0000787 | Caffeine for system suitability | 20 mg |
| EPC0166000 | Calcifediol | 5 mg |
| EPC0166001 | Calcifediol - Reference Spectrum | unit |
| EPY0000499 | Calcipotriol (anhydrous) - Reference Spectrum | unit |
| EPY0000473 | Calcipotriol monohydrate | 5 mg |
| EPY0000474 | Calcipotriol monohydrate - Reference Spectrum | unit |
| EPC0200000 | Calcitonin (salmon) | 2x0.98 mg |
| EPY0000632 | Calcitonin-Gly | 0.4 mL |
| EPC0200010 | N-acetyl-cys1-calcitonin | 0.1 mg |
| EPC0225000 | Calcitriol | 10 mg |
| EPC0226000 | Calcitriol - Reference Spectrum | unit |
| EPC0250000 | Calcium folinate | 100 mg |
| EPC0299000 | Calcium glucoheptonate | 60 mg |
| EPC0300000 | Calcium gluconate | 100 mg |
| EPC0340000 | Calcium levulinate dihydrate | 250 mg |
| EPC0350000 | Calcium oxalate monohydrate | 500 mg |
| EPC0400000 | Calcium pantothenate | 60 mg |
| EPC0405000 | Camphor (racemic) | 50 mg |
| EPC0410000 | Canrenone | 50 mg |
| EPC0426000 | Caprylic acid | 200 mg |
| EPY0000671 | Capsaicin | 50 mg |
| EPC0430000 | Captopril | 10 mg |
| EPY0000113 | Carbachol | 50 mg |
| EPC0450000 | Carbamazepine | 200 mg |
| EPY0000033 | Carbamazepine impurity A 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide (10,11-dihydrocarbamazepine) | 10 mg |
| EPC0451000 | Carbasalate calcium - Reference Spectrum | unit |
| New EPY0001161 | Carbasalate impurity B 2-[[2-(acetyloxy)benzoyl]oxy]benzoic acid (acetylsalicylsalicylic acid) | 5 mg |
| EPC0455000 | Carbenicillin sodium | 50 mg |
| EPC0460000 | Carbidopa | 50 mg |
| EPC0465000 | Carbimazole | 100 mg |
| EPC0470000 | Carbocisteine | 60 mg |
| EPC0499900 | Carbon dioxide - Reference Spectrum | unit |
| EPC0550000 | Carboplatin - Reference Spectrum | unit |
| EPY0000475 | Carboprost trometamol | 40 mg |
| EPY0000536 | Carboprost trometamol - Reference Spectrum | unit |
| EPY0000035 | Carisoprodol | 50 mg |
| EPY0000036 | Carisoprodol impurity A (2RS)-2-(hydroxymethyl)-2-methylpentyl(1-methylethyl)carbamate | 10 mg |
| New EPY0001214 | Carmellose | 10 mg |
| EPC0580004 | Carmustine - Reference Spectrum | unit |
| EPC0580010 | Carmustine impurity A 1,3-bis(2-chloroethyl)urea | 20 mg |
| EPY0000846 | Carprofen for veterinary use | 30 mg |
| EPY0000884 | Carprofen for system suitability | 5 mg |
| EPY0000192 | Carteolol hydrochloride - Reference Spectrum | unit |
| EPY0000193 | Carteolol for system suitability | 30 mg |
| EPY0000075 | Carvedilol - Reference Spectrum | unit |
| EPY0000103 | Carvedilol impurity C (2RS)-1-[benzyl[2-(2-methoxyphenoxy)ethyl]amino]-3-(9H-carbazol-4-yloxy) propan-2-ol | 10 mg |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|---|---------|
| EPC0600000 | Casein BRP | 100 g |
| EPC0630000 | Cefaclor | 450 mg |
| EPC0640000 | Delta-3-Cefaclor | 20 mg |
| EPC0650000 | Cefadroxil | 250 mg |
| EPC0675000 | Cefalexin monohydrate | 150 mg |
| EPC0682000 | Cefalotin sodium | 100 mg |
| EPY0000505 | Cefalotin for impurity B identification | 10 mg |
| EPC0682300 | Cefamandole nafate | 125 mg |
| EPY0000240 | Cefapirin sodium | 100 mg |
| EPC0682400 | Cefatrizine propylene glycol | 150 mg |
| EPC0682410 | Cefatrizine impurity A 7-amino-(6R,7R)-3-[(2H-1,2,3-triazol-4-yl)sulfanyl]-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid(7-ACA triazole) | 60 mg |
| EPC0682800 | Cefazolin | 150 mg |
| EPY0000633 | Cefepime dihydrochloride monohydrate | 150 mg |
| EPY0000634 | Cefepime dihydrochloride monohydrate for system suitability | 15 mg |
| EPC0684000 | Cefixime | 200 mg |
| EPC0684750 | Cefoperazone dihydrate | 100 mg |
| EPC0684800 | Cefoperazone sodium - Reference Spectrum | unit |
| EPY0000420 | Cefotaxime acid | 80 mg |
| EPC0685000 | Cefotaxime sodium | 30 mg |
| EPY0000506 | Cefotaxime sodium for peak identification | 10 mg |
| EPC0688000 | Cefoxitin sodium | 100 mg |
| EPC0690000 | Cefradine | 300 mg |
| EPY0001111 | Ceftazidime for peak identification | 10 mg |
| EPY0000568 | Cefradine for peak identification | 6 mg |
| New EPY0001174 | Cefradine impurity mixture | 0.04 mg |
| EPC0690500 | Ceftazidime | 200 mg |
| EPC0690510 | Ceftazidime impurity A (6R,7R)-7-[[[(Z)-2-(2-aminothiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-8-oxo-3-[(1-pyridinio)-methyl]-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylate (delta-2-ceftazidime)] | 15 mg |
| EPC0691000 | Ceftriaxone sodium | 80 mg |
| EPC0692000 | Ceftriaxone impurity A E-isomer | 10 mg |
| EPC0694990 | Cefuroxime axetil | 60 mg |
| EPC0695000 | Cefuroxime sodium | 150 mg |
| EPY0000311 | Celiprolol hydrochloride | 10 mg |
| EPY0000312 | Celiprolol impurity I 1-acetyl-1-(4-ethoxyphenyl)-3,3-diethylurea | 0.02 mg |
| EPY0000239 | Celiprolol for peak identification | 20 mg |
| EPY0000784 | Cellulose acetate | 40 mg |
| EPC0698005 | Cellulose acetate butyrate - Reference Spectrum | unit |
| EPY0001054 | Cellulose acetate phthalate | 10 mg |
| EPC0700000 | Cephaeline hydrochloride | 15 mg |
| EPC0980650 | Cetirizine dihydrochloride | 100 mg |
| EPC0980651 | Cetirizine impurity A (RS)-1-[(4-chlorophenyl)phenylmethyl]piperazine | 10 mg |
| EPC0984100 | Cetostearyl isononanoate - Reference Spectrum | unit |
| EPC0990000 | Cetyl alcohol | 250 mg |
| EPY0000073 | Cetyl palmitate 15 | 60 mg |
| EPY0000074 | Cetyl palmitate 95 | 50 mg |

| Code | Product | Unit |
|------------|--|-----------|
| EPC1000000 | Cetylpyridinium chloride | 50 mg |
| EPC1050000 | Chenodeoxycholic acid | 125 mg |
| EPY0000104 | Chitosan hydrochloride | 30 mg |
| EPC1100000 | Chlorambucil | 100 mg |
| EPC1200000 | Chloramphenicol | 500 mg |
| EPC1300000 | Chloramphenicol dipalmitate | 100 mg |
| EPC1350000 | Chloramphenicol disodium disuccinate | 25 mg |
| EPC1400000 | Chloramphenicol palmitate isomer | 100 mg |
| EPC1425000 | Chloramphenicol sodium succinate | 1500 mg |
| EPC1435000 | Chlorcyclizine hydrochloride | 100 mg |
| EPC1450000 | Chlordiazepoxide Controlled Substance | 2 x 50 mg |
| EPC1500000 | Chlordiazepoxide hydrochloride Controlled Substance | 100 mg |
| EPY0000476 | Chlordiazepoxide impurity A 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 4-oxide | 10 mg |
| EPC1510000 | Chlorhexidine | 50 mg |
| EPC1520000 | Chlorhexidine diacetate | 10 mg |
| EPC1540000 | Chlorhexidine dihydrochloride | 50 mg |
| EPC1530000 | Chlorhexidine for performance test | 50 mg |
| EPY0000569 | Chlorogenic acid | 20 mg |
| EPC1600000 | Chloromethylnitroimidazole | 100 mg |
| EPC2223030 | 1-(4-Chlorophenyl)-1-phenylethanol Clemastine fumarate impurity C | 20 mg |
| EPC1650000 | Chloroquine sulphate | 200 mg |
| EPC1700000 | Chlorothiazide | 100 mg |
| EPC1800000 | Chlorphenamine maleate | 100 mg |
| EPY0000436 | Chlorphenamine impurity A 2-(4-chlorophenyl)-4-(dimethylamino)-2-[2-(dimethylamino)ethyl]butanenitrile | 0.01 mg |
| EPY0000437 | Chlorphenamine impurity C (3RS)-3-(4-chlorophenyl)-N-methyl-3-(pyridin-2-yl)propan-1-amine | 10 mg |
| EPC1900000 | Chlorpromazine hydrochloride | 200 mg |
| EPY0000507 | Chlorpromazine impurity A 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine S-oxide (chlorpromazine sulphoxide) | 10 mg |
| EPY0000479 | Chlorpromazine impurity D 3-(2-chloro-10H-phenothiazin-10-yl)-N-methylpropan-1-amine (demethylchlorpromazine) | 10 mg |
| EPY0000508 | Chlorpromazine impurity E 2-chloro-10H-phenothiazine | 10 mg |
| EPC1905000 | Chlorpropamide | 100 mg |
| EPC1905020 | Chlorpropamide impurity B 1,3-Dipropylurea | 50 mg |
| EPC1915000 | Chlorprothixene hydrochloride | 50 mg |
| EPC1950000 | Chlortalidone | 150 mg |
| EPY0000779 | Chlortalidone for peak identification | 1 mg |
| EPC2000000 | Chlortetracycline hydrochloride | 100 mg |
| EPC2100000 | Cholecalciferol | 500 mg |
| EPC2150000 | Cholecalciferol for system suitability | 1 mL |
| EPC2155000 | Cholesterol | 60 mg |
| EPC2158000 | Cholic acid | 60 mg |
| EPY0000280 | Chondroitin sulphate sodium | 250 mg |
| EPY0000593 | Chondroitin sulphate sodium (marine) | 100 mg |
| EPC2160000 | Chymotrypsin BRP | 100 mg |
| EPY0000040 | Ciclopirox | 100 mg |
| EPC2162701 | Ciclopirox impurity A (RS)-2-(3-cyclohexyl-5-methyl-4,5-dihydroisoxazol-5-yl)acetic acid | 20 mg |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|--|-----------|
| EPC2162702 | Ciclopirox impurity B 6-cyclohexyl-4-methyl-2H-pyran-2-one | 20 mg |
| EPC2162700 | Ciclopirox olamine | 150 mg |
| EPC2163000 | Ciclosporin | 120 mg |
| EPY0000361 | Ciclosporin for system suitability | 5 mg |
| EPC2170000 | Cilastatin sodium | 10 mg |
| EPC2174000 | Cilazapril | 50 mg |
| EPC2174002 | Cilazapril impurity A 1,1-dimethylethyl(1S,9S)-9-[[[(S)-1-ethoxycarbonyl-3-phenylpropyl]amino]-10-oxo-octahydro-6H-pyridazino[1,2a][1,2]diazepine-1-carboxylate | 25 mg |
| EPC2174005 | Cilazapril impurity D (1S,9S)-9-[[[(R)-1-ethoxycarbonyl-3-phenylpropyl]amino]-10-oxo-octahydro-6H-pyridazino[1,2a][1,2]diazepine-1-carboxylic acid | 10 mg |
| EPC2175000 | Cimetidine | 50 mg |
| EPC2175500 | Cimetidine hydrochloride | 100 mg |
| New EPY0001130 | Cimetidine for peak identification | 10 mg |
| New EPY0001146 | Cimetidine for system suitability | 0.5085 mg |
| EPC2177000 | Cinchocaine hydrochloride | 60 mg |
| EPY0000176 | Cineole | 180 mg |
| EPC2180000 | Cinnarizine | 100 mg |
| EPY0000362 | Ciprofibrate | 5 mg |
| EPY0000363 | Ciprofibrate for system suitability | 5 mg |
| EPY0000198 | Ciprofloxacin | 20 mg |
| EPC2190000 | Ciprofloxacin hydrochloride | 100 mg |
| EPY0000199 | Ciprofloxacin hydrochloride for peak identification | 10 mg |
| EPC2190050 | Ciprofloxacin impurity A 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (fluoroquinolonic acid) | 10 mg |
| EPC2205000 | Cisapride monohydrate | 30 mg |
| EPC2205100 | Cisapride tartrate | 100 mg |
| EPC2210000 | Cisplatin | 100 mg |
| EPY0001018 | Cisplatin impurity A trans-diamminedichloroplatinium (II) | 10 mg |
| EPY0001019 | Cisplatin impurity B amminetrichloroplatinate (-) | 10 mg |
| EPY0001007 | Citalopram hydrochloride | 5 mg |
| EPY0001008 | Citalopram hydrobromide | 5 mg |
| EPY0000855 | Citalopram for system suitability | 0.06 mg |
| EPA1202000 | Citric acid (anhydrous) | 50 mg |
| EPC2219000 | Citric acid monohydrate | 50 mg |
| EPY0000639 | Cladribine | 50 mg |
| EPY0000609 | Cladribine for peak identification | 10 mg |
| EPY0000610 | Cladribine impurity C 2-chloro-7H-purin-6-amine | 5 mg |
| EPY0000320 | Clarithromycin | 160 mg |
| EPY0000321 | Clarithromycin for peak identification | 30 mg |
| EPY0000262 | Clazuril for veterinary use - Reference Spectrum | unit |
| EPY0000269 | Clazuril for system suitability | 10 mg |
| EPC2221000 | Clebopride malate | 100 mg |
| EPC2223000 | Clemastine fumarate | 100 mg |
| EPC2248000 | Clenbuterol hydrochloride | 30 mg |
| EPC2248010 | Clenbuterol impurity B 1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino]ethanone (clenbuterol ketone) | 10 mg |
| EPC2250000 | Clindamycin hydrochloride | 200 mg |

| Code | Product | Unit |
|-----------------------|--|---------|
| EPC2269000 | Clindamycin phosphate | 250 mg |
| EPY0000364 | Clioquinol | 5 mg |
| EPY0000205 | Clobazam - Reference Spectrum | unit |
| EPY0000241 | Clobazam impurity A 7-chloro-5-phenyl-1,5-dihydro-1,5-dihydro-3H-1,5-benzodiazepine-2,4-dione | 10 mg |
| EPY0000559 | Clobetasol propionate | 40 mg |
| EPY0000570 | Clobetasol for peak identification | 2 mg |
| EPY0000571 | Clobetasol impurity J (17R)-4'-chloro-5'-ethyl-9-fluoro-11 β -hydroxy-16 β -methylspiro[androsta-1,4-diene-17,2'(3'H)-furan]-3,3'-dione (17 alpha-spiro compound) | 0.4 mg |
| EPC2285000 | Clobetasone butyrate | 50 mg |
| New EPY0001137 | Clobetasone butyrate for system suitability | 30 mg |
| EPY0000888 | Clodronate disodium tetrahydrate | 5 mg |
| EPY0000885 | Clodronate impurity D (chloromethylene)bis(phosphonic acid) | 5 mg |
| EPY0000313 | Clofazimine | 150 mg |
| EPY0000358 | Clofazimine for system suitability | 10 mg |
| EPC2300000 | Clofibrate | 0.5 mL |
| EPC2320000 | Clomifene citrate | 50 mg |
| EPC2332000 | Clomifene citrate for performance test | 50 mg |
| EPC2360000 | Clomipramine hydrochloride | 100 mg |
| EPY0000132 | Clomipramine impurity C 3-(3-chloro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine | 10 mg |
| EPY0000133 | Clomipramine impurity D 3-(3,7-dichloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl) N,N-dimethylpropan-1-amine | 10 mg |
| EPY0000134 | Clomipramine impurity F 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine | 5 mg |
| EPC2385000 | Clonazepam Controlled Substance | 50 mg |
| EPC2385015 | Clonazepam impurity B 3-Amino-4-(2-chlorophenyl)-6-nitro-1H-quinolin-2-one | 25 mg |
| EPY0000286 | Clonazepam - Reference Spectrum | unit |
| EPC2400000 | Clonidine hydrochloride | 100 mg |
| EPY0000801 | Clonidine impurity B 1-acetyl-2-[(2,6-dichlorophenyl)amino]-4,5-dihydro-1H-imidazole | 20 mg |
| EPY0000833 | Clopidamide | 40 mg |
| EPY0000848 | Clopidamide for system suitability | 10 mg |
| EPY0000392 | Closantel sodium dihydrate | 20 mg |
| EPY0000393 | Closantel for system suitability | 20 mg |
| EPC2424400 | Clostridia (multi-component) rabbit antiserum (for vaccines-vet.use) BRP | 1 mg |
| EPC2424550 | Clostridium tetani guinea pig antiserum (for vaccines-human use) BRP | 3x1 mL |
| EPC2424500 | Clostridium tetani guinea pig antiserum (for vaccines - vet.use) BRP | 1 mg |
| EPC2425600 | Clostridium tetani rabbit antiserum (for vaccines - vet.use) BRP | 1 mg |
| EPC2430000 | Clotrimazole | 100 mg |
| EPY0000818 | Clotrimazole impurity E (2-chlorophenyl)phenylmethanone (2-chlorobenzophenone) | 10 mg |
| EPY0000849 | Clotrimazole for peak identification | 1 mg |
| EPC2450000 | Cloxacillin sodium | 200 mg |
| EPC2460000 | Clozapine | 60 mg |
| EPY0000758 | Clozapine for peak identification | 0.41 mg |
| EPY0000162 | Cocaine hydrochloride - Reference Spectrum | unit |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|---|---------|
| EPC2480000 | Cocoyl caprylocaprate | 40 mg |
| EPY0000722 | Codeine Controlled Substance | 20 mg |
| EPC2500000 | Codeine - Reference Spectrum | unit |
| EPY0000334 | Codeine impurity A 7,8-didehydro-4,5 α -epoxy-3,6 α -dimethoxy-17-methylmorphinan (methycodine) Controlled Substance | 10 mg |
| EPC2500100 | Codeine hydrochloride dihydrate - Reference Spectrum | unit |
| EPC2510000 | Codergocrine mesilate | 60 mg |
| EPC2580000 | Colchicine | 50 mg |
| EPY0000209 | Colchicine for system suitability | 10 mg |
| EPY0000374 | Colestyramine | 10 mg |
| EPC2600000 | Colistimethate sodium | 20 mg |
| EPY0000277 | Colistin sulphate | 25 mg |
| EPC2700000 | Colistin sulphate for microbiological assay | 25 mg |
| EPC2725000 | Copovidone - Reference Spectrum | unit |
| EPC2800000 | Cortisone acetate | 250 mg |
| EPY0000438 | Coumarin | 80 mg |
| EPC2900000 | Cotton wool standard for neps | 1000 mg |
| EPY0001053 | Crospovidone | 5 mg |
| EPC2970000 | Crotamiton | 100 mg |
| EPC2970005 | Crotamiton impurity A N-ethyl-N-(2-methylphenyl)but-3-enamide | 30 mg |
| EPY0001061 | Cyanidin chloride | 20 mg |
| EPC3000000 | Cyanocobalamin | 20 mg |
| EPC3090000 | Cyclizine hydrochloride | 50 mg |
| EPY0000886 | Cyclizine impurity A 1-methylpiperazine | 15 mg |
| EPY0000887 | Cyclizine impurity B diphenylmethanol (benzhydrol) | 10 mg |
| EPC3200000 | Cyclobenzaprine hydrochloride | 100 mg |
| EPC3230000 | Cyclohexa-1,4-dienylglycine | 20 mg |
| EPC3245000 | Cyclopentolate hydrochloride | 2x50 mg |
| EPY0001088 | Cyclopentolate for system suitability | 60 mg |
| EPC3250000 | Cyclophosphamide | 50 mg |
| EPC3280000 | Cyproheptadine hydrochloride | 30 mg |
| EPY0001095 | Cyproheptadine impurity C | 5 mg |
| EPC3283000 | Cyproterone acetate | 30 mg |
| New EPY0001223 | Cyproterone impurity mixture | 0.01 mg |
| EPC3290000 | Cysteine hydrochloride monohydrate | 50 mg |
| EPC3300000 | Cystine | 100 mg |
| EPC3350000 | Cytarabine | 150 mg |
| EPY0000733 | Dacarbazine | 20 mg |
| EPY0000734 | Dacarbazine impurity A 3,7-dihydro-4H-imidazo[4,5-d]-1,2,3-triazin-4-one (2-azahypoxanthine) | 10 mg |
| EPY0000735 | Dacarbazine impurity B 5-amino-1H-imidazole-carboxamide | 10 mg |
| EPD0070000 | Dalteparin sodium | 250 mg |
| EPY0000600 | Danaparoid sodium | 10 mg |
| EPD0100000 | Dapsone | 100 mg |
| EPD0125000 | Daunorubicin hydrochloride | 100 mg |
| EPD0120000 | Daunorubicinone Daunorubicin aglycone | 10 mg |
| EPD0160000 | Deferoxamine mesilate | 30 mg |

| Code | Product | Unit |
|-----------------------|--|----------|
| EPD0201000 | Dehydrohexetidine | 50 mg |
| EPY0000611 | Dembrexine hydrochloride monohydrate | 10 mg |
| EPD0300000 | Demeclocycline hydrochloride | 100 mg |
| EPD0350000 | N-Demethylerythromycin A | 10 mg |
| EPY0000228 | Demethylflumazenil - Reference Spectrum | unit |
| EPD0406000 | Deoxyminoxidil | 0.25 mg |
| EPD0406200 | Deptropine citrate | 60 mg |
| EPD0430000 | Dequalinium chloride | 50 mg |
| EPD0431000 | Dequalinium chloride for performance test | 50 mg |
| EPD0480000 | Desacetylvinblastine | 2x1 mg |
| EPY0000879 | Desflurane - Reference Spectrum | unit |
| EPY0000807 | Desflurane impurity A 1,1'-oxybis(1,2,2,2-tetrafluoroethane) | 1 mL |
| EPD0500000 | Desipramine hydrochloride | 100 mg |
| EPD0600000 | Deslanoside | 150 mg |
| EPD0630000 | Desmethylmetrifonate | 30 mg |
| EPD0650000 | Desmopressin | 0.98 mg |
| EPY0000509 | Desogestrel | 50 mg |
| EPY0000510 | Desogestrel for system suitability | 10 mg |
| EPD0400000 | Desoxycortone acetate | 100 mg |
| EPY0000001 | Detomidine hydrochloride | 100 mg |
| EPD0660020 | Detomidine impurity B (RS)-(1-benzyl-1H-imidazol-5-yl)(2,3-dimethylphenyl)methanol | 20 mg |
| EPD0700000 | Dexamethasone | 60 mg |
| New EPY0001177 | Dexamethasone for system suitability | 10 mg |
| EPD0710000 | Dexamethasone acetate | 100 mg |
| New EPY0001169 | Dexamethasone acetate impurity E 9-fluoro-11beta,17-dihydroxy-16alpha-methyl-3,20-dioxopregn-4-en-21-yl acetate | 0.013 mg |
| EPY0000538 | Dexamethasone isonicotinate | 10 mg |
| EPY0000511 | Dexamethasone isonicotinate for impurity C identification | 10 mg |
| EPD0718000 | Dexamethasone pivalate | 50 mg |
| EPD0720000 | Dexamethasone sodium phosphate | 50 mg |
| EPD0720800 | Dexchlorpheniramine maleate | 60 mg |
| EPD0730000 | Dexpanthenol | 5 mg |
| EPD0731000 | Dextran | 25 mg |
| EPD0731005 | Dextran 1 | 50 mg |
| EPD0732000 | Dextran Vo | 10 mg |
| EPD0733000 | Dextran 4 for calibration | 50 mg |
| EPD0734000 | Dextran 10 for calibration | 50 mg |
| EPD0735000 | Dextran 40 for calibration | 50 mg |
| EPD0736000 | Dextran 70 for calibration | 50 mg |
| EPD0737000 | Dextran 250 for calibration | 50 mg |
| EPD0738000 | Dextran 40 for performance test | 50 mg |
| EPD0739000 | Dextran 60/70 for performance test | 50 mg |
| EPY0000744 | Dextranomer | 50 mg |
| EPD0740000 | Dextromethorphan hydrobromide | 100 mg |
| EPY0000261 | Dextromethorphan impurity A ent-3-methoxymorphinan | 5 mg |
| New EPY0001058 | Dextropropoxyphene hydrochloride Controlled Substance | 10 mg |
| EPY0001150 | Dextropropoxyphene for system suitability Controlled Substance | 5 mg |
| EPD0750000 | Dextropropoxyphene hydrochloride - Reference Spectrum | unit |
| EPD0940000 | Diazepam Controlled Substance | 30 mg |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|--|----------|
| EPY0000596 | Diazepam for system suitability Controlled Substance | 0.5 mg |
| EPD0950000 | Diazoxide | 50 mg |
| EPD0970000 | Dibenzocycloheptene | 20 mg |
| EPD1000000 | Dibenzosuberone | 100 mg |
| EPY0000480 | Dibrompropamide diisetonate | 10 mg |
| EPY0000481 | Dibrompropamide for system suitability | 20 mg |
| EPD1010000 | Dibutyl phthalate | 1 mL |
| EPY0000275 | Dichlorodiaminocyclohexaneplatinum | 10 mg |
| EPY0000259 | Diclazuril for system suitability | 20 mg |
| EPY0000264 | Diclazuril for veterinary use - Reference Spectrum | unit |
| EPD1039990 | Diclofenac potassium | 100 mg |
| EPD1040000 | Diclofenac impurity A 1-(2,6-dichlorophenyl)-indolin-2-one | 0.005 mg |
| EPD1050000 | Dicloxacin sodium | 250 mg |
| EPD1060000 | Dicycloverine hydrochloride | 100 mg |
| EPY0000439 | Didanosine | 10 mg |
| EPY0000440 | Didanosine for system suitability | 10 mg |
| EPY0000441 | Didanosine impurity A 1,7-dihydro-6H-purin-6-one (hypoxanthine) | 10 mg |
| EPY0000442 | Didanosine impurity G 9-(2,3-dideoxy-β-D-glycero-pentofuranosyl)-9H-purin-6-amine (2',3'-dideoxyadenosine) | 10 mg |
| EPD1200000 | Dienestrol | 150 mg |
| EPD1250000 | Diethanolamine fusidate | 50 mg |
| EPD1300000 | Diethylcarbamazine citrate | 250 mg |
| EPY0000217 | Diethylene glycol (monoethyl ether) - Reference Spectrum | unit |
| EPD1410000 | Diethyl phthalate | 1 mL |
| EPD1500000 | Diethylstilbestrol | 100 mg |
| EPD1600000 | Diethylstilbestrol dimethyl ether | 10 mg |
| EPD1700000 | Diethylstilbestrol monomethyl ether | 10 mg |
| EPD1750000 | Diflunisal | 30 mg |
| EPD1800000 | Digitoxin | 250 mg |
| EPY0000640 | Digoxigenin | 5 mg |
| EPD1900000 | Digoxin | 30 mg |
| EPY0000554 | Digoxin for peak identification | 10 mg |
| EPD1940001 | Dihydralazine sulphate (hydrated) - Reference Spectrum | unit |
| EPY0000232 | Dihydralazine for system suitability | 10 mg |
| EPY0000216 | Dihydrocodeine hydrogen tartrate - Reference Spectrum | unit |
| EPY0000053 | 17 alpha-dihydroequilin | 10 mg |
| EPD1945000 | Dihydroergocristine mesilate | 250 mg |
| EPD1950000 | Dihydroergotamine mesilate | 100 mg |
| EPY0000831 | Dihydroergotamine for peak identification | 10 mg |
| EPD1952000 | Dihydroergotamine tartrate | 150 mg |
| EPD1954000 | Dihydrostreptomycin sulphate (for LC assay) | 25 mg |
| EPY0000544 | Dihydrotachysterol | 10 mg |
| EPY0000482 | Dihydrotachysterol for system suitability | 5 mg |
| EPD1980000 | Diltiazem hydrochloride | 200 mg |
| New EPY0001141 | Diltiazem for system suitability | 10 mg |
| EPD2000000 | Dimenhydrinate | 100 mg |
| EPY0000234 | N,N-Dimethylacetamide - Reference Spectrum | unit |
| EPY0001103 | Dimenhydrinate for peak identification | 1 mg |
| EPD2050000 | Dimethyl sulfoxide | 1 mL |

| Code | Product | Unit |
|-----------------------|---|--------|
| EPD2200000 | Dimeticone | 200 mg |
| EPD2205000 | Dimetindene maleate | 50 mg |
| EPD2255000 | Dinoprost trometamol | 60 mg |
| EPD2250000 | Dinoprostone | 100 mg |
| EPD2250015 | Dinoprostone impurity C (E)-7-[(1S,2R,3R)-3-hydroxy-2-[(E)-(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]-hept-5-enoic acid (5-trans-PGE ₂ ; (5E)-PGE ₂) | 10 mg |
| EPY0000094 | Diosmin | 50 mg |
| EPY0000095 | Diosmin for system suitability | 5 mg |
| EPD2600000 | Diphenhydramine hydrochloride | 100 mg |
| EPY0000135 | Diphenhydramine impurity A 2-(diphenylmethoxy)-N-methylethanamine | 10 mg |
| EPD2630000 | Diphenoxylate hydrochloride - Reference Spectrum | unit |
| EPY0000258 | Diphtheria toxin BRP | 1 mL |
| EPD2700000 | Diphtheria vaccine (absorbed) BRP | 32 mg |
| EPY0000376 | Dipivefrine hydrochloride | 100 mg |
| EPY0000394 | Dipivefrine for system suitability | 10 mg |
| EPD2750100 | Dipotassium clorazepate - Reference Spectrum | unit |
| EPD2800000 | Diprophylline | 100 mg |
| EPD2850000 | Dipyridamole | 50 mg |
| EPY0000802 | Dipyridamole for peak identification | 2 mg |
| EPD2880000 | Dirithromycin | 100 mg |
| EPD2900000 | Disodium edetate | 100 mg |
| EPD2920000 | Disopyramide | 100 mg |
| EPD2922000 | Disopyramide phosphate | 100 mg |
| EPD2950000 | Disulfiram | 100 mg |
| EPD2953000 | Dithranol | 125 mg |
| EPD2953025 | Dithranol impurity C Dithranol-dimer 4,4',5,5'-tetrahydroxy-9,9'-bianthracenyl-10,10'(9H,9'H)-dione | 20 mg |
| EPD2953050 | Dithranol impurity D 1-hydroxyanthracen-9(10H)-one | 20 mg |
| EPD2954000 | Dobutamine hydrochloride | 100 mg |
| New EPY0001239 | Dobutamine impurity mixture | 0.1 mg |
| New EPY0001133 | Docetaxel trihydrate | 160 mg |
| New EPY0001155 | Docetaxel for system suitability | 10 mg |
| EPD2954600 | Docosahexaenoic acid ethyl ester | 150 mg |
| EPD2954500 | Docusate sodium - Reference Spectrum | unit |
| EPY0000365 | Dodecyl gallate | 30 mg |
| EPD2955000 | Domperidone | 150 mg |
| EPD2957000 | Domperidone maleate | 150 mg |
| EPD2960000 | Dopamine hydrochloride | 50 mg |
| EPY0000612 | Dopexamine dihydrochloride | 10 mg |
| EPY0000613 | Dopexamine impurity B 2-methoxy-4-[2-[[6-[(2-phenylethyl)hexyl]amino]ethyl]phenol | 10 mg |
| EPY0000614 | Dopexamine impurity F 4-Chloro-5-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]benzene-1,2-diol | 10 mg |
| EPY0000726 | Dorzolamide hydrochloride | 50 mg |
| EPY0000727 | Dorzolamide impurity A (4R,6R)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulphonamide 7,7-dioxide | 5 mg |
| EPY0000750 | Dorzolamide for system suitability | 5 mg |
| EPD2962000 | Dosulepin hydrochloride | 100 mg |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|---|----------|
| EPD2962005 | Dosulepin impurity A (E)-3-(6,11-dihydrodibenzo[b,e]thiepin-11-ylidene)- N,N'-dimethylpropan-1-amine S-oxide | 50 mg |
| EPD2963000 | Doxapram hydrochloride | 50 mg |
| EPY0000208 | Doxapram impurity B (4RS)-1-ethyl-4-[2-[(2-hydroxyethyl)amino]ethyl]-3,3-diphenylpyrolidin-2-one | 10 mg |
| EPY0000553 | Doxazosin mesilate | 60 mg |
| EPY0000551 | Doxazosin impurity D 6,7-dimethoxyquinazoline-2,4(1H,3H)-dione | 10 mg |
| EPY0000552 | Doxazosin impurity F 2-chloro-6,7-dimethoxyquinazolin-4-amine | 10 mg |
| EPY0000838 | Doxepin hydrochloride | 5 mg |
| EPY0000851 | Doxepin for system suitability | 1 mg |
| EPD2975000 | Doxorubicin hydrochloride | 150 mg |
| EPD3000000 | Doxycycline hyclate | 50 mg |
| EPY0000163 | Doxylamine hydrogen succinate - Reference Spectrum | unit |
| EPY0000160 | Doxylamine impurity A N,N-dimethyl-2-[1(RS)-1-phenyl-1-(pyridin-4-yl)ethoxy]ethanamine | 50 mg |
| EPD3100000 | Droperidol | 150 mg |
| New EPY0001105 | Drospirenone | 60 mg |
| New EPY0001115 | Drospirenone impurity E 3-oxo-6 α ,7 α ,15 α ,16 α -tetrahydro-3'H,3"H-dicyclopropa[6,7:15,16]pregn- 4-ene-21,17- carbolactone (17-epidrospirenone) | 0.06 mg |
| EPY0001004 | Dydrogesterone | 50 mg |
| EPY0001005 | Dydrogesterone impurity A 9 β ,10-pregna-4,6,8(14)-triene-3,20-dione | 6 mg |
| EPY0001006 | Dydrogesterone impurity B pregna-4,6-diene-3,20-dione | 5 mg |
| EPY0000249 | Ebastine - Reference Spectrum | unit |
| EPY0000247 | Ebastine impurity C 4-(diphenylmethoxy)piperidine | 10 mg |
| EPY0000248 | Ebastine impurity D 1-[4-(1,1-dimethylethyl)phenyl]-4-(4-hydroxypiperidin-1-yl)butan-1-one | 10 mg |
| New EPY0001236 | Econazole | 10 mg |
| EPY0000270 | Econazole - Reference Spectrum | unit |
| EPY0000254 | Econazole for system suitability | 20 mg |
| EPE0050000 | Econazole nitrate | 100 mg |
| EPY0000296 | Econazole nitrate - Reference Spectrum | unit |
| EPE0085000 | Eicosapentaenoic acid ethyl ester | 200 mg |
| EPY0000537 | Emedastine difumarate | 10 mg |
| EPY0000512 | Emedastine impurity E 1-(2-ethoxyethyl)-2-(hexahydro-1H-1,4-diazepin-1yl)benzimidazole | 10 mg |
| EPE0100000 | Emetine hydrochloride | 100 mg |
| EPE0110000 | Enalapril for system suitability | 20 mg |
| EPE0109000 | Enalapril maleate | 50 mg |
| New EPY0001211 | Enalapril impurity mixture | 0.06 mg |
| EPY0000615 | Enalaprilat dihydrate | 100 mg |
| EPY0000629 | Enalaprilat for system suitability | 10 mg |
| EPY0000678 | Enalaprilat impurity G (2SR)-2-[(3SR,8aRS)-3-methyl-1,4-dioxohexahydropyrrolo [1,2-a]pyrazin-2(1H)-4-phenylbutanoic acid | 0.005 mg |
| EPY0000136 | Enilconazole | 60 mg |
| EPY0000137 | Enilconazole impurity E (1RS)-1-(2,4-dichlorophenyl)-2-(-1H-imidazol-1-yl)ethanol | 20 mg |
| EPE0150000 | Endotoxin standard BRP | 11 mg |
| EPE0180000 | Enoxaparin sodium | 200 mg |

| | Code | Product | Unit |
|------------|------------|---|---------|
| | EPE0180500 | Enoxolone | 100 mg |
| New | EPY0001259 | Enrofloxacin | 5 mg |
| New | EPY0001160 | Enrofloxacin for system suitability | 10 mg |
| | EPE0200000 | Enterokinase BRP | 500 mg |
| | EPE0305000 | Ephedrine hydrochloride (racemic) Drug Precursor | 50 mg |
| | EPE0300000 | Ephedrine hydrochloride Drug Precursor | 150 mg |
| | EPE0400000 | 4-Epianhydrotetracycline hydrochloride | 15 mg |
| | EPE0430000 | 4-Epichlortetracycline hydrochloride | 20 mg |
| | EPE0440000 | 4-Epidemeclocycline hydrochloride | 20 mg |
| | EPE0500000 | 6-Epidoxycycline hydrochloride | 50 mg |
| New | EPY0001139 | Epinastine hydrochloride | 20 mg |
| New | EPY0001128 | Epinastine hydrochloride for system suitability | 10 mg |
| | EPE0530000 | 4-Epioxytetracycline | 40 mg |
| | EPE0550000 | Epirubicin hydrochloride | 100 mg |
| | EPE0600000 | 4-Epitetracycline hydrochloride | 30 mg |
| | EPY0000052 | Equilin | 15 mg |
| | EPE0850010 | Eq influenza Subtype 1 Strain A/eq/Newmarket/77 Horse Antiserum BRP | 3x1 mg |
| | EPE0850021 | Eq influenza Subtype 2 American-like/Newmarket Horse Antiserum BRP | 3x1 mg |
| | EPE0850022 | Eq Influenza Subtype 2 European-like/Newmarket Horse Antiserum BRP | 3x1 mg |
| | EPY0000712 | Eq Influenza Subtype 2 American-like/South Africa Horse Antiserum BRP | 3x1 mg |
| | EPE0900000 | Ergocalciferol | 500 mg |
| | EPE1000000 | Ergometrine maleate Drug Precursor | 50 mg |
| | EPE1100000 | Ergosterol | 20 mg |
| | EPE1200000 | Ergotamine tartrate Drug Precursor | 100 mg |
| | EPY0000051 | Erysipelas ELISA coating antigen BRP | 0.4 mg |
| | EPY0000177 | Erythritol | 1000 mg |
| | EPE1300000 | Erythromycin for microbiological assay | 250 mg |
| | EPE1305000 | Erythromycin A | 250 mg |
| | EPE1310000 | Erythromycin B | 50 mg |
| | EPE1320000 | Erythromycin C | 50 mg |
| | EPE1400000 | Erythromycin estolate | 100 mg |
| | EPE1500000 | Erythromycin ethylsuccinate | 100 mg |
| | EPE1500800 | Erythromycin stearate | 50 mg |
| | EPE1515000 | Erythropoietin BRP | 37.5 mg |
| | EPY0000324 | Esketamine hydrochloride - Reference Spectrum | unit |
| | EPY0000338 | Esketamine impurity D (2R)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone ((R)-ketamine) Controlled Substance | 10 mg |
| | EPY0001028 | Esomeprazole magnesium trihydrate | 10 mg |
| | EPY0000749 | Essential oil | 1000 mg |
| | EPE1600000 | Estradiol benzoate | 250 mg |
| | EPY0000852 | Estradiol benzoate for system suitability | 10 mg |
| | EPY0000045 | Estradiol butyrate | 10 mg |
| | EPE1620000 | Estradiol hemihydrate | 100 mg |
| | EPY0000314 | Estradiol for peak identification | 10 mg |
| | EPY0000046 | Estradiol valerate | 50 mg |
| | EPE1680000 | Estriol | 50 mg |
| | EPE1680005 | Estriol impurity A 9,11-didehydroestriol | 20 mg |
| | EPE1700000 | Estrone | 15 mg |
| | EPE1800000 | Etacrynic acid | 100 mg |
| New | EPY0001263 | Etacrynic acid for system suitability | 10 mg |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|---|--------------|
| EPE1830000 | Etamsylate | 30 mg |
| EPE1840000 | Ethacridine lactate monohydrate | 50 mg |
| EPE1850000 | Ethambutol hydrochloride | 250 mg |
| EPY0000803 | Ethambutol for system suitability | 10 mg |
| EPA1202800 | Ethanol (anhydrous) - Reference Spectrum | unit |
| EPE1860100 | Ethanol 96% - Reference Spectrum | unit |
| EPE1900000 | Ethinylestradiol | 100 mg |
| New EPY0001124 | Ethinylestradiol for system suitability | 25.3 mg |
| EPE2000000 | Ethionamide | 100 mg |
| EPE2150000 | Ethosuximide | 30 mg |
| EPE2250000 | Ethosuximide impurity A 2-Ethyl-2-methylsuccinic acid | 15 mg |
| EPE2195000 | Ethyl acetate - Reference Spectrum | unit |
| EPE2195900 | Ethylcellulose - Reference Spectrum | unit |
| EPE2202000 | 1-N-Ethylgaramin sulphate | 50 mg |
| EPE2205500 | 1,1'-Ethylidenebistryptophan | 2x0.00158 mg |
| EPY0000617 | Ethyl indole-3-carboxylate | 10 mg |
| EPE2300000 | Ethylmorphine hydrochloride - Reference Spectrum | unit |
| EPE2400000 | Ethylnicotinamide | 150 mg |
| EPE2425000 | Ethyl parahydroxybenzoate | 50 mg |
| EPE2450000 | Etifenin | 25 mg |
| EPE2451000 | Etilefrine hydrochloride | 75 mg |
| EPE2451010 | Etilefrine impurity A 2-ethylamino-1-(3-hydroxyphenyl)ethanone | 20 mg |
| EPY0000572 | Etidronate disodium | 10 mg |
| EPE2470000 | Etodolac | 60 mg |
| EPE2470050 | Etodolac impurity H 2-(7-ethylindol-3-yl)ethanol | 10 mg |
| EPY0000768 | Etodolac for peak identification | 10 mg |
| EPE2499900 | Etofenamate | 40 mg |
| EPE2499901 | Etofenamate for peak identification | 15 mg |
| EPE2499914 | Etofenamate impurity G 2-hydroxyethyl 2-[[3-(trifluoromethyl)phenyl]amino]-benzoate | 20 mg |
| EPE2500000 | Etofylline | 100 mg |
| EPE2503000 | Etomidate | 100 mg |
| EPE2503004 | Etomidate impurity B methyl-1-[(1RS)-1-phenylethyl]-1H-imidazole-5-carboxylate | 25 mg |
| EPE2600000 | Etoposide | 150 mg |
| EPE5000000 | Eugenol | 500 µL |
| EPF0005000 | Famotidine | 100 mg |
| EPY0000382 | Famotidine for system suitability | 10 mg |
| EPF0007000 | Famotidine impurity B 3,5-bis[2-[[[2-[(diaminomethylene)amino]thiazol-4-yl]methyl]thio]-ethyl]-4H-1,2,4,6-thiatriazine 1,1-dioxide | 10 mg |
| EPY0000409 | Famotidine impurity D 3-[[[2-[(diaminomethylene)amino]thiazol-4-yl]methyl]sulphonyl]propanamide | 10 mg |
| EPY0000556 | Febantel | 110 mg |
| EPY0000660 | Febantel for system suitability | 10 mg |
| EPY0000731 | Felbinac | 10 mg |
| EPY0000732 | Felbinac impurity A 4-acetyl biphenyl | 20 mg |
| EPF0030000 | Felodipine | 120 mg |
| EPY0000415 | Felypressin | 0.994 mg |
| EPF0040000 | Fenbendazole | 150 mg |

| Code | Product | Unit |
|-----------------------|---|---------|
| EPF0040010 | Fenbendazole impurity A methyl(1 <i>H</i> -benzimidazol-2-yl)carbamate | 20 mg |
| EPF0040020 | Fenbendazole impurity B methyl[5(6)-chlorobenzimidazol-2-yl]carbamate | 20 mg |
| EPF0041000 | Fenbufen | 100 mg |
| EPF0048000 | Fenofibrate | 100 mg |
| EPF0048005 | Fenofibrate impurity A (4-chlorophenyl)(4-hydroxyphenyl)methanone | 20 mg |
| EPF0048010 | Fenofibrate impurity B 2[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid (fenofibric acid) | 10 mg |
| EPF0048035 | Fenofibrate impurity G 1-methylethyl 2-[[2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoyl]oxy]-2-methylpropanoate | 25 mg |
| EPY0000756 | Fenoterol for peak identification | 1.2 mg |
| EPF0050000 | Fenoterol hydrobromide | 100 mg |
| EPF0054990 | Fentanyl - Reference Spectrum | unit |
| EPF0055000 | Fentanyl citrate - Reference Spectrum | unit |
| EPF0060000 | Fenticonazole nitrate | 50 mg |
| EPF0060040 | Fenticonazole impurity D (<i>RS</i>)-1-[2-(2,4-dichlorophenyl)-2-hydroxyethyl]-3-[4-(phenylsophanyl)benzyl]imidazolium nitrate | 20 mg |
| EPF0100000 | Ferrous gluconate | 100 mg |
| EPY0001013 | Ferulic acid | 20 mg |
| EPY0000789 | Fexofenadine hydrochloride | 60 mg |
| EPY0000751 | Fexofenadine impurity A 2-[4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butanoyl]phenyl]-2-methylpropanoic acid | 5 mg |
| EPY0000752 | Fexofenadine impurity B 2-[3-[(1 <i>RS</i>)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid | 0.01 mg |
| EPY0000753 | Fexofenadine impurity C (1 <i>RS</i>)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]-1-[4-(1-methylethyl)phenyl]butan-1-ol | 5 mg |
| New EPY0001173 | Filgrastim | 0.2 mL |
| EPY0000090 | Finasteride | 60 mg |
| EPY0000091 | Finasteride for system suitability | 100 mg |
| EPY0000736 | Flavoxate hydrochloride | 10 mg |
| EPY0000737 | Flavoxate impurity A 3-methyl-4-oxo-2-phenyl-4 <i>H</i> -1-benzopyran-8-carboxylic acid | 10 mg |
| EPY0000738 | Flavoxate impurity B ethyl 3-methyl-4-oxo-2-phenyl-4 <i>H</i> -1-benzopyran-8-carboxylate | 10 mg |
| EPF0120000 | Flecainide acetate | 200 mg |
| EPF0120005 | Flecainide impurity A 3-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-1,5,6,7,8,8a-hexahydroimidazo[1,5- <i>a</i>]pyridine | 50 mg |
| EPF0120010 | Flecainide impurity B (piperidin-2-yl)methanamine | 25 mg |
| EPY0000138 | Flubendazole | 25 mg |
| EPY0000139 | Flubendazole for system suitability | 20 mg |
| EPY0000892 | Flucloxacillin magnesium octahydrate | 5 mg |
| EPY0000889 | Flucloxacillin impurity C 6-aminopenicillanic acid | 5 mg |
| EPY0000890 | Flucloxacillin impurity D 3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylic acid | 5 mg |
| EPY0000891 | Flucloxacillin impurity E 6-aminopenicillanic acid flucloxacillin amide | 5 mg |
| EPF0150000 | Flucloxacillin sodium | 250 mg |
| EPY0000557 | Fluconazole | 50 mg |
| EPY0000558 | Fluconazole for peak identification | 10 mg |

European Pharmacopoeia

| Code | Product | Unit |
|------------|---|-----------|
| EPY0000573 | Fluconazole impurity B 2-[2-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol | 10 mg |
| EPY0000574 | Fluconazole impurity C 1,1'-(1,3-phenylene)di-1H-1,2,4-triazole | 5 mg |
| EPF0175000 | Flucytosine | 100 mg |
| EPY0000419 | Fludarabine phosphate | 100 mg |
| EPF0180000 | Fludrocortisone acetate | 100 mg |
| EPF0188000 | Flumazenil - Reference Spectrum | unit |
| EPY0000335 | Flumazenil impurity B ethyl 8-hydroxy-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate | 5 mg |
| EPF0189000 | Flumequine | 60 mg |
| EPF0189020 | Flumequine impurity B ethyl(RS)-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-benzo[i,j]quinolizine-2-carboxylate (flumequine ethyl ester) | 0.1 mg |
| EPF0188500 | Flumetasone pivalate | 100 mg |
| EPF0189900 | Flunarizine dihydrochloride | 100 mg |
| EPY0000265 | Flunarizine dihydrochloride - Reference Spectrum | unit |
| EPY0000266 | Flunarizine dihydrochloride for system suitability | 20 mg |
| EPF0190000 | Flunitrazepam Controlled Substance | 100 mg |
| EPY0000169 | Flunitrazepam - Reference Spectrum | unit |
| EPY0000443 | Flunixin meglumine | 10 mg |
| EPY0000444 | Flunixin impurity B 2-methyl-3-(trifluoromethyl)aniline | 10 mg |
| EPY0000445 | Flunixin impurity C ethyl 2-chloropyridine-3-carboxylate | 50 mg |
| EPF0200000 | Fluocinolone acetonide | 100 mg |
| EPF0230000 | Fluocortolone pivalate | 100 mg |
| EPY0000796 | Fluorescein | 120 mg |
| EPY0000804 | Fluorescein impurity C 2-(2,4-dihydroxybenzoyl)benzoic acid | 0.01 mg |
| EPY0000454 | Diacetylfluorescein | 100 mg |
| EPF0245000 | Fluoresceine sodium - Reference Spectrum | unit |
| EPF0250000 | Fluorouracil | 50 mg |
| EPY0000762 | Fluorouracil impurity A pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) | 10 mg |
| EPY0000763 | Fluorouracil impurity B dihydropyrimidine-2,4,5(3H)-trione (isobarbituric acid or 5-hydroxyuracil) | 10 mg |
| EPY0000764 | Fluorouracil impurity C pyrimidine-2,4(1H,3H)-dione (uracil) | 10 mg |
| EPY0000765 | Fluorouracil impurity F 2-ethoxy-5-fluoropyrimidin-4(1H)-one (2-ethoxy-5-fluorouracil) | 10 mg |
| EPY0000791 | Fluorouracil impurity mixture | 0.0002 mg |
| EPF0253000 | Fluoxetine hydrochloride | 250 mg |
| EPF0253020 | Fluoxetine impurity B methyl(3-phenylpropyl)amine Controlled Substance | 5 mg |
| EPF0253030 | Fluoxetine impurity C (RS)-methyl-[3-phenyl-3-(3-trifluoromethylphenoxy)-propyl]amine | 5 mg |
| EPY0000064 | Flupentixol dihydrochloride | 100 mg |
| EPY0000067 | Flupentixol impurity D 2-[2-[4-[3-[(EZ)-2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethoxy]ethanol | 15 mg |
| EPY0000078 | Flupentixol impurity F 2-[4-[(EZ)-3-[(9RS)-2-(trifluoromethyl)-9H-thioxanthen-9-yl]prop-2-enyl]-piperazin-1-yl]ethanol | 25 mg |
| EPF0260000 | Fluphenazine decanoate | 60 mg |
| EPY0000009 | Fluphenazine enantate | 100 mg |

| Code | Product | Unit |
|-----------------------|---|----------|
| EPF0280000 | Fluphenazine dihydrochloride | 50 mg |
| EPY0000708 | Fluphenazine impurity mixture | 0.07 mg |
| EPY0000298 | Fluphenazine octanoate | 10 mg |
| EPY0000299 | Fluphenazine sulphoxide | 10 mg |
| EPY0000211 | Flurazepam monohydrochloride - Reference Spectrum | unit |
| EPF0285200 | Flurbiprofen | 50 mg |
| EPF0285202 | Flurbiprofen impurity A (2RS)-2-(biphenyl-4-yl)propanoic acid | 20 mg |
| EPY0000236 | Fluspirilene | 20 mg |
| EPY0000375 | Fluspirilene impurity C 8-[4,4-bis((4-fluorophenyl)butyl)-3-(hydroxymethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one | 10 mg |
| EPF0285600 | Flutamide | 50 mg |
| EPF0285603 | Flutamide impurity C N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide | 20 mg |
| EPY0000284 | Fluticasone propionate | 100 mg |
| EPY0000221 | Fluticasone impurity D S-methyl 6a,9a-difluoro-11b-hydroxy-16a-methyl-3-oxo-17a-propionyloxy-androsta-1,4-diene-17β-carbothioate (S-methyl derivative) | 10 mg |
| EPF0290000 | Flutrimazole | 100 mg |
| EPF0290010 | Flutrimazole impurity B (RS)-(2-fluorophenyl)(4-fluorophenyl)phenylmethanol | 60 mg |
| EPY0001090 | Fluvastatin sodium | 110 mg |
| EPY0001082 | Fluvastatin for system suitability | 0.5 mg |
| EPY0000854 | Fluvoxamine maleate | 5 mg |
| EPY0000853 | Fluvoxamine for system suitability | 1.004 mg |
| EPY0000916 | Fluvoxamine impurity D 5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one | 10 mg |
| EPY0000386 | Foeniculin for peak identification Star anise oil | 100 mg |
| EPF0300000 | Folic acid | 250 mg |
| New EPY0001242 | Folic acid impurity A (2S)-2-[(4-aminobenzoyl)amino]pentanedioic acid (N-(4-aminobenzoyl)-l-glutamic acid) | 15 mg |
| New EPY0001243 | Folic acid impurity D 4-[[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzoic acid (pteroic acid) | 50 mg |
| EPF0372000 | Formoterol fumarate dihydrate | 10 mg |
| EPY0000339 | Formoterol for impurity I identification | 10 mg |
| EPY0000340 | Formoterol fumarate for system suitability | 10 mg |
| EPF0380000 | Formylfolic acid 10-Formylfolic acid | 30 mg |
| EPF0389000 | Foscarnet sodium hexahydrate | 50 mg |
| EPF0389004 | Foscarnet impurity B disodium(ethoxyoxydophosphanyl)formate | 10 mg |
| New EPY0001222 | Foscarnet impurity D | 50 mg |
| New EPY0001213 | Foscarnet impurity mixture | 0.012 mg |
| EPF0399900 | Fosfomycin calcium - Reference Spectrum | unit |
| EPF0399950 | Fosfomycin sodium - Reference Spectrum | unit |
| EPF0400000 | Fosfomycin trometamol | 1500 mg |
| New EPY0001227 | Fosinopril sodium | 60 mg |
| New EPY0001228 | Fosinopril impurity A | 5 mg |
| New EPY0001229 | Fosinopril impurity B | 5 mg |
| New EPY0001230 | Fosinopril impurity C mixture of (2S,4S)-4-cyclohexyl-1-[[[(S)-[(1S)-2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid and (2S,4S)-4-cyclohexyl-1-[[[(R)-[(1R)-2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid | 10 mg |

European Pharmacopoeia

| | Code | Product | Unit |
|------------|------------|--|----------|
| New | EPY0001231 | Fosinopril impurity D (2S,4R)-4-cyclohexyl-1-[[[R]-[(1S)-2-methyl-1-(1-oxopropoxy)propoxy]](4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid | 10 mg |
| New | EPY0001232 | Fosinopril impurity I | 5 mg |
| New | EPY0001233 | Fosinopril impurity K | 5 mg |
| New | EPY0001212 | Fosinopril impurity mixture | 0.02 mg |
| | EPF0450000 | Framycetin sulphate | 2x25 mg |
| | EPF0550000 | Fructose | 100 mg |
| | EPF0600000 | Fumaric acid | 100 mg |
| | EPF0700000 | Furosemide | 100 mg |
| | EPF0702000 | Furosemide impurity A 2-chloro-4-(furfurylamino)-5-sulphamoylbenzoic acid | 5 mg |
| | EPF1000000 | Fusidic acid - Reference Spectrum | unit |
| | EPG0049000 | Galactitol | 50 mg |
| | EPG0050000 | Galactose | 60 mg |
| New | EPY0001279 | Galantamine hydrobromide | 10 mg |
| New | EPY0001190 | Galantamine natural for system suitability | 10 mg |
| New | EPY0001201 | Galantamine racemic mixture | 10 mg |
| New | EPY0001191 | Galantamine synthetic for system suitability | 5 mg |
| | EPG0100000 | Gallamine triethiodide | 100 mg |
| | EPG0150000 | Gammacyclodextrin | 50 mg |
| New | EPY0001129 | Ganciclovir | 220 mg |
| New | EPY0001144 | Ganciclovir impurity mixture | 0.005 mg |
| | EPY0000675 | Gemcitabine hydrochloride | 50 mg |
| | EPY0000676 | Gemcitabine impurity A 4-aminopyrimidin-2(1H)-one (Cytosine) | 20 mg |
| | EPY0000513 | Gemfibrozil | 5 mg |
| | EPY0000514 | Gemfibrozil for system suitability | 0.196 mg |
| | EPG0200000 | Gentamicin sulphate | 2x25 mg |
| New | EPY0001112 | Gestodene | 100 mg |
| | EPY0001110 | Gestodene for system suitability | 10 mg |
| | EPY0001116 | Gestodene impurity I 13-ethyl-17-hydroxy-5-methoxy-18,19-dinor-5alpha,17alpha-pregn-15-en-20-yn-3-one | 0.01 mg |
| | EPY0001012 | Ginkgo dry extract for peak identification | 150 mg |
| | EPY0001010 | Ginkgolic Acid | 20 mg |
| | EPG0300000 | Gitoxin | 30 mg |
| | EPG0325000 | Glibenclamide | 100 mg |
| | EPG0325010 | Glibenclamide impurity A 4-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulphonamide | 10 mg |
| | EPY0000242 | Glibenclamide impurity B methyl [[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl] sulphonyl]carbamate | 10 mg |
| | EPG0326000 | Gliclazide | 20 mg |
| | EPG0326004 | Gliclazide impurity B 2-nitroso-octahydrocyclopenta[c]pyrrole | 25 mg |
| | EPG0326012 | Gliclazide impurity F 1-(hexahydrocyclopenta[c]pyrrol-2-(1H)-yl-3-[(2-methylphenyl)sulphonyl]urea | 30 mg |
| | EPY0000515 | Glimepiride | 60 mg |
| | EPY0000516 | Glimepiride for system suitability | 0.012 mg |
| | EPG0340000 | Glipizide | 50 mg |
| | EPG0342000 | Glipizide impurity A 4-[2-(5-methylpyrazine-2-carboxamido)ethyl]benzene sulphonamide | 10 mg |
| | EPY0000523 | Glipizide impurity C ethyl 2-[4-[(cyclohexylcarbamoyl)sulphamoyl]phenyl]ethyl]carbamate | 10 mg |

| | Code | Product | Unit |
|------------|------------|--|------------|
| | EPY0000643 | Glipizide impurity D 6-methyl-N-[2-(4-sulphamoylphenyl)ethyl]pyrazine-2-carboxamide | 10 mg |
| New | EPY0001140 | Glipizide impurity mixture | 0.002 mg |
| | EPY0000191 | Human glucagon | 2x0.952 mg |
| | EPG0350500 | Glucose | 100 mg |
| | EPG0355000 | Glutamic acid | 50 mg |
| | EPY0000517 | Glutathione | 10 mg |
| | EPG0360000 | Glutethimide Controlled Substance | 50 mg |
| | EPG0400000 | Glycerol (85 per cent) - Reference Spectrum | unit |
| | EPG0400002 | Glycerol dibehenate | 2000 mg |
| | EPG0400004 | Glycerol distearate | 2000 mg |
| | EPY0000794 | Glycerol monocaprylate | 400 mg |
| | EPY0000795 | Glycerol monocaprylocaprate | 500 mg |
| | EPG0400006 | Glycerol monolinoleate | 2000 mg |
| | EPG0400007 | Glycerol mono-oleate | 2000 mg |
| | EPG0400008 | Glycerol monostearate 40-55 | 2000 mg |
| | EPG0400101 | Glyceryl trinitrate - Reference Spectrum | unit |
| | EPG0400100 | Glyceryl trinitrate solution | 0.5 mL |
| | EPG0450000 | Glycine | 50 mg |
| | EPY0000433 | Ammonium glycyrrhizate | 70 mg |
| | EPG0460000 | Glycyrrhizate (monoammonium) | 300 mg |
| | EPG0525000 | Gonadorelin | 5.08 mg |
| | EPY0000125 | Goserelin | 2 mg |
| | EPY0000126 | Gosereline - Reference Spectrum | unit |
| | EPY0000019 | 4-D-Ser-goserelin | 0.1 mg |
| | EPY0000194 | Goserelin validation mixture | 1 mg |
| | EPG0550000 | Gramicidin | 250 mg |
| | EPY0000396 | Granisetron hydrochloride | 120 mg |
| | EPY0000477 | Granisetron impurity A 2-methyl-N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-2H-indazole-3-carboxamide | 1 mg |
| | EPY0000478 | Granisetron impurity B N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide | 1 mg |
| | EPY0000395 | Granisetron impurity E (1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine | 10 mg |
| | EPG0600000 | Griseofulvin | 50 mg |
| | EPY0000619 | Guaiacol | 2200 mg |
| | EPG0700000 | Guaifenesin | 100 mg |
| | EPY0000117 | Halofantrine hydrochloride | 125 mg |
| | EPY0000118 | Halofantrine impurity C [1,3-dichloro-6-(trifluoromethyl)phenantren-9-yl]methanol | 10 mg |
| | EPH0100000 | Haloperidol | 50 mg |
| | EPH0100100 | Haloperidol decanoate | 60 mg |
| | EPH0150000 | Halothane - Reference Spectrum | unit |
| | EPY0000673 | Harpagoside | 1.03 mg |
| | EPH0185000 | Heparin Low-Molecular-Mass for assay BRP | 5x10 mg |
| | EPH0190000 | Heparin Low-Molecular-Mass for calibration CRS | 25 mg |
| | EPH0200000 | Heparin sodium BRP | 2 mL |
| | EPH0205010 | Hepatitis A vaccine (inactivated,absorbed) Type B BRP | 3x0.5 mL |
| New | EPY0001192 | Hepatitis A Vaccine (Inactivated, Non-Adsorbed) | 0.8 ml |
| | EPY0000389 | Hepatitis B vaccine (rDNA) BRP method A (thiomersal free) | 2x0.5 mL |
| | EPH0210010 | Hepatitis B vaccine (rDNA) BRP method B | 2x1 mL |
| | EPH0215000 | Hepatitis C Virus RNA for NAT testing BRP | 5x40 mg |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|--|------------|
| EPH0220000 | Heptadecanol | 2x600 mg |
| EPY0000063 | Heptaminol hydrochloride | 150 mg |
| EPY0000057 | Heptaminol impurity A (2RS)-6-methylhept-5-en-2-amine | 20 mg |
| EPH0250000 | alpha-Hexachlorocyclohexane | 10 mg |
| EPH0330000 | Hexamidine diisetonate | 50 mg |
| EPH0325000 | Hexetidine | 100 mg |
| EPH0400000 | Hexobarbital | 500 mg |
| EPH0420000 | Hexylresorcinol | 100 mg |
| EPH0500000 | Hide Powder | 500 mg |
| EPH0600000 | Histamine dihydrochloride | 250 mg |
| EPH0700000 | Histamine phosphate | 250 mg |
| EPH0750000 | Histidine | 100 mg |
| EPH0755000 | Histidine hydrochloride monohydrate | 100 mg |
| EPH0800000 | Homatropine hydrobromide | 100 mg |
| EPH0830000 | Homatropine methylbromide | 25 mg |
| EPH0837000 | L-Homocysteine thiolactone hydrochloride - Reference Spectrum | unit |
| EPH0900000 | Human albumin for electrophoresis BRP | 1 mL |
| EPY0000219 | Human anti-D immunoglobulin BPR | unit |
| EPY0000667 | Human coagulation factor VII concentrate BRP | 2 x 26 mg |
| EPH0920000 | Human coagulation factor VIII concentrate BRP | 5x34 mg |
| EPH0920500 | Human coagulation factor IX concentrate BRP | 5x30 mg |
| EPH0950000 | Human hepatitis A immunoglobulin BRP | 3x10 mg |
| EPH0990000 | Human immunoglobulin BRP | 15800 mg |
| EPH1000000 | Human immunoglobulin for electrophoresis BRP | 96 mg |
| EPY0000488 | Human immunoglobulin (molecular size) BRP | 3 x 700 mg |
| EPH1005000 | Human Plasma Pools for NAT Validation | 3502 mg |
| EPH1100000 | Human rabies immunoglobulin BRP | 3x170 mg |
| EPH1110000 | Human tetanus immunoglobulin BRP | 87 mg |
| EPY0000502 | Human vaccinia immunoglobulin | 3 x 1 mL |
| EPH1115000 | Hyaluronidase BRP | 50 mg |
| EPH1120000 | Hydralazine hydrochloride | 20 mg |
| New EPY0001151 | Hydrastine hydrochloride | 20 mg |
| EPH1200000 | Hydrochlorothiazide | 150 mg |
| EPY0000646 | Hydrocodone hydrogen tartrate 2.5-hydrate Controlled Substance | 10 mg |
| EPY0000710 | Hydrocodone for peak identification Controlled Substance | 10 mg |
| EPH1300000 | Hydrocortisone | 100 mg |
| New EPY0001092 | Hydrocortisone for peak identification | 5 mg |
| EPH1400000 | Hydrocortisone acetate | 125 mg |
| EPH1425000 | Hydrocortisone hydrogen succinate | 100 mg |
| EPH1426000 | Hydrogenated wool fat | 250 mg |
| EPY0000446 | Hydromorphone hydrochloride Controlled Substance | 10 mg |
| EPB0650000 | Hydrous benzoyl peroxide - Reference Spectrum | unit |
| EPH1428000 | Hydroxocobalamin | 10 mg |
| EPY0000119 | Hydroxycarbamide | 175 mg |
| EPH1429400 | Hydroxyethyl salicylate | 125 mg |
| EPH1429700 | 4-Hydroxyphenoxymethylpenicillin potassium | 20 mg |
| EPH1430000 | D-alpha-(4-Hydroxy-phenyl)glycine | 50 mg |
| EPY0000186 | Hydroxypropylbetadex | 10 mg |
| EPH1435000 | Hydroxyzine hydrochloride | 600 mg |

| Code | Product | Unit |
|-----------------------|---|---------|
| EPY0000011 | Hymecromone | 100 mg |
| EPY0000012 | Hymecromone impurity A Resorcinol | 25 mg |
| EPY0000013 | Hymecromone impurity B 7-hydroxy-2-methyl-4H-1-benzopyran-4-one | 25 mg |
| EPY0000483 | Hyoscine | 10 mg |
| EPY0000484 | Hyoscine impurity A (1R,2R,4S,5S,7s)-3-oxa-9-azatricyclo[3.3.1.0 ^{2,4}]non-7-yl (2S)-3-hydroxy-2-phenylpropanoate (norhyoscine) | 10 mg |
| EPH1450000 | Hyoscine butylbromide | 20 mg |
| EPY0000447 | Hyoscine butylbromide impurity E (1R,2R,4S,5S,7S)-9-butyl-7-[[[(2S)-3-hydroxy-2-phenylpropanoyl]oxy]-3-oxa-9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane | 10 mg |
| EPH1500000 | Hyoscine hydrobromide | 50 mg |
| EPY0000448 | Hyoscine hydrobromide impurity B (1R,2R,4S,5S,7s)-3-oxa-9-azatricyclo[3.3.1.0 ^{2,4}]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate | 10 mg |
| EPH1600000 | Hyoscyamine sulphate | 100 mg |
| EPY0000449 | Hyoscyamine impurity E (1R,3s,5S)-8-azabicyclo[3.2.1] oct-3-yl(2S)-3-hydroxy-2-phenylpropanoate | 10 mg |
| EPY0000915 | Hypromellose phthalate | 10 mg |
| EPI0020000 | Ibuprofen | 160 mg |
| EPB1220000 | Ibuprofen impurity B (2RS)-2-(4-Butylphenyl)propionic acid (0,06% solution in Acetonitrile) | 1.15 mL |
| EPY0000140 | Ibuprofen impurity F 3-[4-(2-methylpropyl)phenyl]propanoic acid | 5 mg |
| EPY0000881 | Ibuprofen for peak identification | 0.09 mg |
| EPI0050000 | Idoxuridine | 50 mg |
| EPI0060000 | Ifosfamide | 50 mg |
| EPI0060100 | Ifosfamide - Reference Spectrum | unit |
| EPI0060002 | Ifosfamide impurity A 3-[(2-chloroethyl)amino]propyl dihydrogen phosphate | 30 mg |
| EPI0060004 | Ifosfamide impurity B bis[3-[(2-chloroethyl)amino]propyl]dihydrogen diphosphate | 20 mg |
| EPI0060010 | Ifosfamide impurity E 3-chloro-N-(2-chloroethyl)propan-1-amine | 10 mg |
| EPI0060012 | Ifosfamide impurity F (RS)-2-chloro-3-(2-chloroethyl)-1,3,2-oxazaphosphinane 2-oxide | 10 mg |
| EPI0086000 | Imidazole | 100 mg |
| EPI0090000 | Imipenem | 100 mg |
| EPI0100000 | Imipramine hydrochloride | 50 mg |
| EPY0000893 | Imipramine for system suitability | 10 mg |
| New EPY0001153 | Immunoglobulin for anti-A, anti-B antibodies limit test | 45 mg |
| EPY0000540 | Immunoglobulin panel for anti-D antibodies test BRP | 2000 mg |
| EPI0150000 | Indapamide | 150 mg |
| EPI0150020 | Indapamide impurity B 4-chloro-3-sulphamoyl-N-(2-methyl-1H-indol-1-yl)benzamide | 5 mg |
| EPY0000788 | Indinavir | 100 mg |
| EPY0000880 | Indinavir sulphate - Reference Spectrum | unit |
| EPY0000746 | Indinavir for system suitability | 20 mg |
| EPI0200000 | Indometacin | 50 mg |
| EPY0000349 | Insulin aspart | 3.89 mg |
| EPI0305000 | Insulin (bovine) | 7.99 mg |
| EPI0310000 | Insulin (human) | 7.03 mg |
| EPY0000348 | Insulin lispro | 5.93 mg |
| EPI0320000 | Insulin (porcine) | 8.61 mg |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|--|----------|
| EPI0320300 | Interferon alfa-2a | 1 mg |
| EPI0320301 | Interferon alfa-2b | 0.2 mL |
| EPI0320330 | Interferon gamma 1b | 2x0.6 mL |
| EPI0320331 | Interferon gamma-1b validation solution | 0.2 mL |
| EPI0328000 | lobenguane sulphate | 25 mg |
| EPY0000839 | lobenguane sulphate - Reference Spectrum | unit |
| EPI0320800 | lohexol | 150 mg |
| EPI0320810 | lohexol impurity A 5-acetamido-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-tri-iodobenzene-1,3- dicarboxamide | 50 mg |
| EPI0320820 | lohexol impurity J 5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-tri-iodobenzene-1,3-dicarboxamide | 125 mg |
| EPY0000672 | lohexol for peak identification | 10 mg |
| EPI0329000 | lopamidol | 50 mg |
| EPI0329010 | lopamidol impurity A N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]- 5-amino-2,4,6-tri-iodoisophthalamide | 10 mg |
| EPY0000406 | lopamidol impurity H 4-chloro-N,N'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)- 5-(2-hydroxypropanoyl)amino)2,6-diiodobenzene-1,3-dicarboxamide | 10 mg |
| EPI0330000 | lopanoic acid | 100 mg |
| EPY0001020 | lopromide | 100 mg |
| New EPY0001077 | lopromide impurity A 5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-N-methylbenzene-1,3- dicarboxamide | 0.125 mg |
| EPY0001021 | lopromide for system suitability 1 | 5 mg |
| EPY0001022 | lopromide for system suitability 2 | 5 mg |
| EPI0340000 | lotalamic acid | 100 mg |
| EPA0560000 | lotalamic acid impurity A 5-Amino-2,4,6-tri-iodo-N-methylisophthalamide acid | 20 mg |
| EPY0000555 | lotrolan | 100 mg |
| EPY0000658 | lotrolan for system suitability | 5 mg |
| EPY0000141 | loxaglic acid | 125 mg |
| EPY0000142 | loxaglic acid impurity A 3-amino-5[[2-hydroxyethyl)amino]carbonyl]-2,4,6-triiodobenzoic acid | 20 mg |
| EPI0360000 | lpratropium bromide | 120 mg |
| EPY0000276 | lpratropium bromide impurity A (1R,3r,5S,8r)-3-hydroxy-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane | 10 mg |
| EPI0361000 | lpratropium bromide impurity B (1R,3r,5S,8s)-3-[[2-(2RS)-3-hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1-methylethyl)- 8-azonia- bicyclo[3.2.1]octane | 10 mg |
| New EPY0001166 | lrbesartan | 60 mg |
| New EPY0001156 | lrbesartan impurity A 1-(pentylamino)-N-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]cyclopentanecarboxamide | 10 mg |
| EPI0375000 | Isoconazole | 200 mg |
| EPI0380000 | Isoconazole nitrate | 200 mg |
| EPI0400000 | Isoemetine hydrobromide | 25 mg |
| EPY0000858 | Isoflurane | 1.5 mL |
| EPY0000037 | Isoflurane - Reference Spectrum | unit |
| EPI0460000 | Isoleucine | 50 mg |
| EPI0465000 | Isomalt | 3000 mg |
| EPY0000070 | Isomaltooligosaccharide | 0.9 mg |
| EPI0500000 | Isoniazid | 100 mg |
| EPI0599990 | Isoprenaline hydrochloride | 50 mg |
| EPI0600000 | Isoprenaline sulphate | 500 mg |
| EPI0725000 | Isopropyl hexadecanoate | 100 mg |
| EPI0750000 | Isopropyl tetradecanoate | 2 mL |

| Code | Product | Unit |
|------------|---|---------|
| EPI0775000 | Isosorbide dinitrate | 300 mg |
| EPI0775010 | Isosorbide mononitrate | 100 mg |
| EPI0775020 | Isosorbide-2-nitrate | 50 mg |
| EPI0800000 | Isotretinoin | 60 mg |
| EPI0900000 | Isoxsuprine hydrochloride | 50 mg |
| EPY0000366 | Isradipine | 125 mg |
| EPY0000367 | Isradipine impurity D methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)- 2,6-dimethylpyridine-3,5-dicarboxylate | 5 mg |
| EPI7000000 | Itraconazole | 150 mg |
| EPY0001100 | Itraconazole for system suitability | 15 mg |
| EPI8000010 | Ivermectin | 150 mg |
| EPY0000575 | Ivy leaf standardised tincture | 2 mL |
| EPY0000041 | Josamycin | 150 mg |
| EPY0000042 | Josamycin propionate | 150 mg |
| EPK0100000 | Kanamycin B sulphate | 20 mg |
| EPK0200000 | Kanamycin monosulphate | 150 mg |
| EPY0000450 | Ketamine hydrochloride Controlled Substance | 10 mg |
| EPK0551000 | Ketamine impurity A 1-[(2-chlorophenyl)(methylimino)methyl]cyclopentanol | 50 mg |
| EPY0000246 | Ketobemidone hydrochloride - Reference Spectrum | unit |
| EPY0000244 | Ketobemidone impurity B 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidyl)ethanone | 5 mg |
| EPY0000245 | Ketobemidone impurity C 1-(4-(3-hydroxyphenyl)-4-piperidyl)propan-1-one | 5 mg |
| EPK0600000 | Ketoconazole | 150 mg |
| EPK1000000 | 3-Ketofusidic acid | 10 mg |
| EPK2000000 | Ketoprofen | 50 mg |
| EPK2000010 | Ketoprofen impurity A 1-(3-benzoylphenyl)ethanone | 10 mg |
| EPK2000015 | Ketoprofen impurity C 3-[(1RS)-1-carboxyethyl]benzoic acid | 5 mg |
| EPY0000486 | Ketorolac trometamol | 10 mg |
| EPY0000626 | Ketorolac trometamol for peak identification | 5 mg |
| EPY0000164 | Ketotifen hydrogen fumarate - Reference Spectrum | unit |
| EPY0000161 | Ketotifen impurity G 4-(1-methylpiperidin-4-ylidene)-4H-benzo(4,5)cyclohepta(1,2-b)thiophen-9,10-dione | 3 mg |
| EPL0050000 | Labetalol hydrochloride | 80 mg |
| EPL0129000 | Lactitol monohydrate | 60 mg |
| EPY0000257 | Lactobionic acid | 100 mg |
| EPA1206000 | Lactose (anhydrous) | 100 mg |
| EPL0100000 | Lactose | 100 mg |
| EPL0130000 | Lactulose | 3000 mg |
| EPY0000188 | Lactulose for system suitability | 12 mg |
| EPY0000425 | Lamivudine | 150 mg |
| EPY0000518 | Lamivudine for system suitability 1 | 10 mg |
| EPY0000426 | Lamivudine for system suitability 2 | 10.3 mg |
| EPY0001030 | Lamotrigine | 10 mg |
| EPY0001031 | Lamotrigine for peak identification | 20 mg |
| EPY0001085 | Lamotrigine for system suitability | 10 mg |
| EPY0001032 | Lamotrigine impurity E 2,3-dichlorobenzoic acid | 10 mg |
| EPY0000773 | Lansoprazole | 60 mg |
| EPY0000774 | Lansoprazole for peak identification | 1 mg |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|---|-----------|
| EPY0000654 | Leflunomide | 100 mg |
| EPY0000487 | Leflunomide impurity A 4-(trifluoromethyl)aniline | 25 mg |
| EPY0000674 | Leflunomide for peak identification | 1 mg |
| EPY0000685 | Letrozole | 70 mg |
| EPL0375000 | Leucine | 50 mg |
| EPL0376000 | Leuprorelin | 0.925 mg |
| EPL0376001 | Leuprorelin - Reference Spectrum | unit |
| EPY0000047 | Levamisole for system suitability | 60 mg |
| EPL0380000 | Levamisole hydrochloride | 50 mg |
| EPY0000048 | Levamisole - Reference Spectrum | unit |
| EPL0390000 | Levocabastine hydrochloride | 125 mg |
| EPL0390008 | Levocabastine impurity D 1-[cis-4-cyano-4-(4-fluorophenyl)cyclohexyl]-4-phenylpiperidine-4-carboxylic acid | 20 mg |
| EPL0399900 | Levocarnitine | 125 mg |
| EPL0399905 | Levocarnitine impurity A (E)-or(Z)-4-(trimethylammonio)but-2-enoate | 50 mg |
| EPL0400000 | Levodopa | 100 mg |
| EPL0420000 | Levodropropizine | 60 mg |
| EPL0420002 | Levodropropizine impurity A (2R)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol(dextrodropropizine) | 20 mg |
| EPY0001033 | Levodropropizine impurity B 1-phenylpiperazine | 50 mg |
| EPY0001048 | Levodropropizine impurity C 2,3-epoxypropan-1-ol | 300 mg |
| EPL0500000 | Levomepromazine hydrochloride | 100 mg |
| EPL0505000 | Levomepromazine maleate | 50 mg |
| EPL0551000 | Levonorgestrel | 30 mg |
| EPL0570000 | Levothyroxine sodium | 100 mg |
| EPL0595000 | Lidocaine | 50 mg |
| EPL0600000 | Lidocaine hydrochloride | 100 mg |
| EPL0650000 | Lincomycin hydrochloride | 250 mg |
| EPL0700000 | Liothyronine sodium | 50 mg |
| EPY0000860 | Liothyronine for peak identification | 0.0046 mg |
| New EPY0001235 | Lisinopril for system suitability | 2 mg |
| EPL0702000 | Lisinopril dihydrate | 50 mg |
| EPL0702100 | Lisinopril dihydrate for performance test | 2x2 mg |
| EPL0720000 | Lithium clavulanate | 125 mg |
| EPL0720800 | Lithocholic acid | 60 mg |
| EPY0000112 | Lobeline hydrochloride | 50 mg |
| EPL0745000 | Lomustine | 50 mg |
| EPL0750000 | Loperamide hydrochloride | 50 mg |
| EPY0000322 | Loperamide hydrochloride for system suitability | 15 mg |
| EPY0000341 | Loperamide oxide monohydrate | 20 mg |
| EPY0000688 | Loratadine | 60 mg |
| EPY0000603 | Loratadine for system suitability | 20 mg |
| EPY0000604 | Loratadine impurity F ethyl 4-[(11RS)-8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta [1,2-b]pyridin-11-yl]piperidine-1-carboxylate | 10 mg |
| EPY0000605 | Loratadine impurity H ethyl 4-oxopiperidine-1-carboxylate | 50 mg |
| EPL0750500 | Lorazepam Controlled Substance | 100 mg |
| EPY0000576 | Lorazepam for system suitability Controlled Substance | 0.8 mg |

| Code | Product | Unit |
|-----------------------|---|-----------|
| EPY0000718 | Lorazepam impurity D (5RS)-7-chloro-5-(2-chlorophenyl)-4,5-dihydro-1H-1,4-benzodiazepine-2,3-dione | 10 mg |
| EPY0001062 | Losartan potassium | 50 mg |
| EPY0001072 | Losartan impurity D 2-butyl-4-chloro-1H-imidazole-5-carbaldehyde | 6 mg |
| EPY0001076 | Losartan for system suitability | 0.0015 mg |
| EPL0790000 | Lovastatin | 40 mg |
| New EPY0001136 | Lovastatin for peak identification | 20 mg |
| EPL0800000 | Lynestrenol | 50 mg |
| EPY0001034 | Lynestrenol for peak identification | 20 mg |
| EPY0000397 | Lysine acetate | 60 mg |
| EPL0900000 | Lysine hydrochloride | 50 mg |
| EPY0000745 | Macrogol 40 sorbitol heptaoleate | 20 mg |
| New EPY0001157 | Macrogol polyvinyl alcohol grafted polymer | 400 mg |
| EPM0088000 | Magnesium aspartate dihydrate | 60 mg |
| EPM0120000 | Malathion | 250 mg |
| EPM0120005 | Malathion impurity A diethyl(2RS)-2-[(methoxy)(methylsulfanyl)-S-phosphinothioyl] butane dioate (isomalathion) | 10 mg |
| EPM0120010 | Malathion impurity B diethyl(2RS)-2-(dimethoxy-S-phosphinothioyl)-butanedioate (maloxon) | 10 mg |
| EPM0100000 | Maleic acid | 100 mg |
| EPY0000143 | Malic acid - Reference Spectrum | unit |
| EPM0160000 | Maltitol | 1200 mg |
| EPM0200000 | Mannitol | 1200 mg |
| EPM0206000 | Maprotiline hydrochloride | 100 mg |
| EPM0206040 | Maprotiline impurity D 3-(9,10-dihydro-9,10-ethanoanthracen-9-yl)-N-methylprop-2-en-1-amine; (dehydromaprotiline) | 25 mg |
| EPY0000819 | Marbofloxacin | 10 mg |
| EPY0000820 | Marbofloxacin for peak identification | 20 mg |
| EPM0210000 | Measles vaccine (live) BRP | 5x80 mg |
| EPM0215000 | Mebendazole | 20 mg |
| EPY0000144 | Mebendazole for system suitability | 20 mg |
| EPY0000168 | Mebendazole - Reference Spectrum | unit |
| EPY0001086 | Mebrofenin | 120 mg |
| EPM0220000 | Meclozine hydrochloride | 150 mg |
| EPM0240000 | Medronic acid | 20 mg |
| New EPY0001199 | Medronic acid impurity A | 60 µl |
| New EPY0001106 | Medronic acid impurity B Tetrakis(1-methylethyl)methylenediphosphonate | 40 µl |
| EPM0250000 | Medroxyprogesterone acetate | 100 mg |
| EPM0250010 | Medroxyprogesterone acetate for performance test | 50 mg |
| EPY0000598 | Medroxyprogesterone acetate for system suitability | 10 mg |
| EPM0252600 | Mefenamic acid | 50 mg |
| EPY0001081 | Mefenamic acid impurity A 2,3-dimethylaniline | 100 mg |
| EPM0253000 | Mefloquine hydrochloride | 100 mg |
| EPM0260100 | Megestrol acetate - Reference Spectrum | unit |
| New EPY0001209 | Meglumine | 10 mg |
| EPY0000267 | Meglumine - Reference Spectrum | unit |
| EPY0001080 | Meloxicam | 50 mg |
| EPY0001035 | Meloxicam impurity A ethyl 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate 1,1-dioxide | 5 mg |

European Pharmacopoeia

| Code | Product | Unit |
|------------|--|---------|
| EPY0001036 | Meloxicam impurity B 5-methylthiazol-2-amine | 5 mg |
| EPY0001037 | Meloxicam impurity C N-[(2Z)-3,5-dimethylthiazol-2(3H)-ylidene]-4-hydroxy-2-methyl-2H-1,2- benzothiazine-3-carboxamide 1,1-dioxide | 5 mg |
| EPY0001039 | Meloxicam impurity D N-[(2Z)-3-ethyl-5-methylthiazol-2(3H)-ylidene]-4-hydroxy-2-methyl-2H-1,2- benzothiazine-3-carboxamide 1,1-dioxide | 5 mg |
| EPM0300000 | Menadione | 100 mg |
| EPM0350000 | Menthol | 150 mg |
| EPM0370000 | Mepivacaine hydrochloride | 100 mg |
| EPM0370020 | Mepivacaine impurity B (RS)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide | 60 mg |
| EPM0400000 | Meprobamate Controlled Substance | 100 mg |
| EPM0500000 | Mepyramine maleate | 1000 mg |
| EPY0000679 | Mepyramine impurity A N-(4-methoxybenzyl)pyridin-2-amine | 10 mg |
| EPY0000680 | Mepyramine impurity C pyridin-2-amine | 10 mg |
| EPY0000297 | Mesalazine | 125 mg |
| EPY0001040 | Mesityl oxid | 100 mg |
| EPY0000337 | Mesna - Reference Spectrum | unit |
| EPY0000316 | Mesna impurity C 2-(acetylsulphonyl)ethanesulphonic acid | 10 mg |
| EPY0000317 | Mesna impurity D 2,2'-(disulphanediyl)bis(ethanesulphonic acid) | 10 mg |
| EPY0000227 | Meso-rich exametazime | 0.5 mg |
| EPY0000097 | Mesterolone | 60 mg |
| EPY0000096 | Mesterolone impurity A 17 β -hydroxy-1 α -methylandroster-4-en-3-one | 30 mg |
| EPM0600000 | Mestranol | 100 mg |
| EPY0000301 | Metacresol - Reference Spectrum | unit |
| EPM0600500 | Metacycline hydrochloride | 50 mg |
| EPM0600900 | Metamizole sodium | 100 mg |
| EPM0600905 | Metamizole impurity A 4-formylamino-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one | 15 mg |
| EPM0605000 | Metformin hydrochloride | 50 mg |
| EPY0000770 | Methacrylic acid-ethylacrylate copolymer (1:1) type A | 200 mg |
| EPY0000323 | Methacrylic acid-ethyl acrylate copolymer (1:1) - type B | 200 mg |
| EPM0610000 | Methacrylic acid-ethylacrylate copolymer (1:1) - Reference Spectrum | unit |
| EPM0610030 | Methacrylic acid-ethyl acrylate copolymer (1:1), dispersion 30% - Reference Spectrum | unit |
| EPM0620000 | Methacrylic acid-methylmethacrylate copolymer (1:1) - Reference Spectrum | unit |
| EPM0630000 | Methacrylic acid-methylmethacrylate copolymer (1:2) - Reference Spectrum | unit |
| EPM0800000 | Methadone hydrochloride - Reference Spectrum | unit |
| EPY0000428 | Methanol - Reference Spectrum | unit |
| EPM0900000 | Methaqualone - Reference Spectrum | unit |
| EPY0000754 | Methenamine | 10 mg |
| EPM0950000 | DL-Methionine | 50 mg |
| EPM0960000 | Methionine | 50 mg |
| EPM1000000 | Methotrexate | 100 mg |
| EPY0000602 | Methotrexate for peak identification | 20 mg |
| EPY0000663 | Methotrexate impurity C (2S)-2-[[4-[[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]methylamino]benzoyl]amino]pentanedioic acid (N-methylfolic acid, methopteridine) | 10 mg |

| Code | Product | Unit |
|------------|--|----------|
| EPM1000008 | Methotrexate impurity D 4-[[[(2-amino-4hydroxypteridin-6-yl)methyl]methyl-amino]benzoic acid | 10 mg |
| EPY0000664 | Methotrexate impurity E 4-[[[(2,4-diaminopteridin-6-yl)methyl]methylamino]benzoic acid (4-amino-N10-methylpteroic acid, APA) | 10 mg |
| EPM1100000 | 3-Methoxymethyl dopa | 20 mg |
| EPM1300000 | Methylatropine bromide | 100 mg |
| EPM1400000 | Methylatropine nitrate | 100 mg |
| EPM1450000 | Methylcarbidopa | 1 mg |
| EPM1470000 | Methyl 2-(4-chlorophenoxy)-2-methylpropionate | 0.5 mL |
| EPM1500000 | Methyldopa | 50 mg |
| EPY0001083 | Methyldopa for system suitability | 0.024 mg |
| EPM1550000 | Methylene chloride | 2 mL |
| EPM1551000 | 2-(1-Methylethyl)pentanoic acid | 25 mg |
| EPM1556000 | Methyl 12-hydroxystearate | 100 mg |
| EPY0000398 | Methyl nicotinate | 25 mg |
| EPY0000776 | Methylergometrine maleate | 10 mg |
| EPY0000777 | Methylergometrine for system suitability | 0.53 mg |
| EPM1625000 | Methylnitrosoindoline | 100 mg |
| EPM1650000 | Methyl parahydroxybenzoate | 50 mg |
| EPY0001017 | Methylphenidate hydrochloride Controlled Substance | 40 mg |
| EPY0000910 | Methylphenidate impurity mixture | 0.04 mg |
| EPM1700000 | Methylphenobarbital Controlled Substance | 500 mg |
| EPM1750000 | Methylprednisolone | 150 mg |
| EPM1755000 | Methylprednisolone acetate | 100 mg |
| EPM1755200 | Methylprednisolone hydrogen succinate | 125 mg |
| EPM1755220 | Methylprednisolone hydrogen succinate for performance test | 50 mg |
| EPY0000190 | N-Methylpyrrolidone - Reference Spectrum | unit |
| EPM1770180 | Methyl ricinoleate | 125 mg |
| EPY0000418 | Methylrosanilinium chloride | 40 mg |
| EPY0000407 | Methylrosanilinium chloride for system suitability | 10 mg |
| EPM1770200 | Methyl stearate | 100 mg |
| EPM1800000 | Methyltestosterone | 100 mg |
| EPY0000861 | Methyltestosterone for system suitability | 10 mg |
| EPM1800900 | Methylthionium chloride | 50 mg |
| EPM1800902 | Methylthionium impurity A 3-(dimethylamino)-7-(methylamino)phenothiazin-5-ylum | 20 mg |
| EPM1808000 | Metixene hydrochloride | 75 mg |
| EPM1824990 | Metoclopramide | 100 mg |
| EPM1825000 | Metoclopramide hydrochloride | 50 mg |
| EPM1824995 | Metoclopramide impurity A 4-(acetilamino)-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide | 25 mg |
| EPM1825010 | Metoclopramide impurity E N,N-diethylethane-1,2-diamine | 20 mg |
| EPY0000701 | Metolazone | 80 mg |
| EPY0000702 | Metolazone for system suitability | 10 mg |
| EPY0000171 | Metoprolol succinate - Reference Spectrum | unit |
| EPM1830000 | Metoprolol tartrate | 60 mg |
| EPY0000145 | Metoprolol impurity A (2RS)-1-(ethylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol | 10 mg |
| EPM1845000 | Metrifonate | 100 mg |
| EPM1850000 | Metronidazole | 50 mg |
| EPM1851000 | Metronidazole benzoate | 50 mg |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|---|---------|
| EPY0000069 | Metronidazole benzoate - Reference Spectrum | unit |
| EPY0000087 | Metronidazole impurity A 2-methyl-4-nitroimidazole | 10 mg |
| EPM1860000 | Mexiletine hydrochloride | 100 mg |
| EPY0000202 | Mexiletine impurity C 1,1'-[(3,3',5,5'-tetramethylbiphenyl-4,4'-diyl)bisoxy] dipropan-2-amine | 2 mg |
| EPY0000203 | Mexiletine impurity D (2RS)-2-(2,6-dimethylphenoxy)propan-1-amine | 2 mg |
| EPM1875000 | Mianserin hydrochloride | 50 mg |
| EPY0001041 | Mianserin impurity B (14bRS)-2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine-8-sulfonic acid | 10 mg |
| EPY0000862 | Mianserin hydrochloride for system suitability | 1.01 mg |
| EPM1880000 | Miconazole | 70 mg |
| EPM1900000 | Miconazole nitrate | 100 mg |
| EPM2200000 | Midazolam Controlled Substance | 50 mg |
| EPY0000562 | Midazolam impurity C acide 8-chloro-6-(2-fluorophenyl)-1-methyl-4 <i>H</i> -imidazo[1,5- <i>a</i>][1,4]benzodiazepine-3-carboxylique | 0.08 mg |
| EPY0000599 | Midazolam for system suitability Controlled Substance | 1 mg |
| EPY0000539 | Milk thistle standardised dry extract | 120 mg |
| EPM2280000 | Minocycline hydrochloride | 125 mg |
| EPM2300000 | Minoxidil | 50 mg |
| EPY0000705 | Mirtazapine | 10 mg |
| EPY0000721 | Mirtazapine for system suitability | 10 mg |
| EPY0000490 | Misoprostol | 30 mg |
| EPY0000491 | Misoprostol impurity A mixture of methyl 7-[(1RS,2SR, 3SR)-3-hydroxy-2-[(1E,4RS)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate and methyl- 7-[(1RS,2SR,3SR)-3-hydroxy-2-[(1E,4SR)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate (8-epimisoprostol) | 5 mg |
| New EPY0001162 | Misoprostol for system suitability | 5 mg |
| EPY0000378 | Mitomycin | 120 mg |
| EPM2305000 | Mitoxantrone hydrochloride | 60 mg |
| EPM2305005 | Mitoxantrone impurity A 1-amino-5,8-dihydroxy-4-[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthracene-9,10-dione | 5 mg |
| EPY0000635 | Modafinil | 110 mg |
| EPY0000636 | Modafinil for system suitability | 0.1 mg |
| EPY0000251 | Molgramostim | 0.3 mL |
| EPY0000821 | Molsidomine | 5 mg |
| EPY0000822 | Molsidomine impurity B N-Nitrosomorpholine | 10 mg |
| EPY0000823 | Molsidomine impurity D morpholine-4-carbaldehyde | 10 mg |
| EPM2900000 | Mometasone furoate | 100 mg |
| EPY0000028 | Morantel hydrogen tartrate | 50 mg |
| EPY0000451 | Morphine hydrochloride Controlled Substance | 25 mg |
| EPY0000452 | Morphine sulphate Controlled Substance | 40 mg |
| EPY0000830 | Morphine for system suitability Controlled Substance | 10 mg |
| EPY0000772 | Moxidectin | 70 mg |
| EPY0000747 | Moxidectin for system suitability | 10 mg |
| EPY0000703 | Moxifloxacin hydrochloride | 110 mg |
| EPY0000717 | Moxifloxacin for peak identification | 10 mg |
| EPY0000226 | Moxonidine | 50 mg |
| EPY0000222 | Moxonidine impurity A 4,6-dichloro-N-(imidazolidin-2-ylidene)-2-methylpyrimidin-5-amine | 10 mg |

| Code | Product | Unit |
|------------|--|----------|
| EPM3600000 | Mumps vaccine (live) BRP | 5x33 mg |
| EPM3805000 | Mupirocin - Reference Spectrum | unit |
| EPM3805500 | Mupirocin calcium - Reference Spectrum | unit |
| EPM3806000 | Mupirocin lithium | 100 mg |
| EPY0000489 | Mycophenolate mofetil | 30 mg |
| EPY0000519 | Mycophenolate mofetil for peak identification | 10 mg |
| EPY0000692 | Mycoplasma fermentans BRP | 1 mL |
| EPY0000690 | Mycoplasma hyorhinis BRP | 1 mL |
| EPY0000691 | Mycoplasma orale BRP | 1 mL |
| EPY0000689 | Mycoplasma synoviae BRP | 1 mL |
| EPY0000485 | Myo-inositol | 1020 mg |
| EPN0020000 | Nabumetone | 60 mg |
| EPN0020020 | Nabumetone impurity D (E)-4-(6-methoxynaphthalen-2-yl)but-3-en-2-one | 10 mg |
| EPN0020030 | Nabumetone impurity F 6,6'-dimethoxy-2,2'-binaphthalenyl | 10 mg |
| EPY0000146 | Nadolol | 100 mg |
| EPN0025000 | Nadroparin calcium | 250 mg |
| EPY0000077 | Naftidrofuryl - Reference Spectrum | unit |
| EPY0000120 | Naftidrofuryl impurity A 2-[(naphthalen-1-yl)methyl]-3-(tetrahydrofuran-2-yl)propanoic acid* | 10 mg |
| EPY0000121 | Naftidrofuryl impurity B ethyl 2-[(naphthalen-1-yl)methyl]-3-(tetrahydrofuran-2-yl)propanoate | 25 mg |
| EPY0000331 | Naftidrofuryl impurity F 2-[(diethylamino)ethyl 2-[(naphthalen-2-yl)methyl]-3-(tetrahydrofuran-2-yl) propanoate | 10 mg |
| EPN0050000 | Nalidixic acid | 100 mg |
| EPN0075000 | Naloxone hydrochloride dihydrate | 100 mg |
| EPY0000695 | Naloxone for peak identification | 10 mg |
| EPY0000400 | Naltrexone hydrochloride | 50 mg |
| EPY0000410 | Naltrexone impurity C N-(3-butenyl)-noroxymorphone | 15 mg |
| EPY0000542 | Nandrolone decanoate | 5 mg |
| EPY0000547 | Nandrolone decanoate for peak identification | 10 mg |
| EPY0000548 | Nandrolone decanoate for system suitability | 10 mg |
| EPN0080000 | Naphazoline hydrochloride | 50 mg |
| EPN0100000 | Naphazoline nitrate | 10 mg |
| EPN0200000 | Naphazoline impurity A N-(2-aminoethyl)-2-(naphthalen-1-yl)acetamide (Naphthylacetylthylenediamine) | 10 mg |
| EPN0250000 | Naproxen | 100 mg |
| EPY0000399 | Naproxen (racemic) | 10 mg |
| EPY0000631 | Naproxen impurity L 1-(6-Methoxynaphthalen-2-yl)ethanone (Acetylnorlin) | 10 mg |
| EPN0300000 | Neamine | 0.5 mg |
| EPN0399000 | Neohesperidin dihydrochalcone | 125 mg |
| EPN0399004 | Neohesperidin dihydrochalcone impurity B 7-[[2-O-(6-deoxy- α -L-mannopyranosyl)- β -D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one (neodiosmin) | 10 mg |
| EPN0400000 | Neomycin sulphate | 50 mg |
| EPN0401000 | Neomycin sulphate for microbiological assay | 25 mg |
| EPN0500000 | Neostigmine bromide | 50 mg |
| EPN0550000 | Neostigmine metilsulfate | 50 mg |
| EPN0559000 | Netilmicin sulphate | 2x25 mg |
| EPY0000520 | Nevirapine (anhydrous) | 30 mg |
| EPY0000521 | Nevirapine for peak identification | 0.058 mg |

European Pharmacopoeia

| Code | Product | Unit |
|------------|---|----------|
| EPY0000388 | Newcastle Disease Vaccine (inactivated) BRP | 4 uc |
| EPY0000287 | Nicergoline - Reference Spectrum | unit |
| EPY0000283 | Nicergoline impurity A [(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindol [4,3-fg]quinolin-9-yl]methyl 5-chloropyridine-3-carboxylate | 10 mg |
| EPN0560000 | Niclosamide (anhydrous) | 50 mg |
| EPN0600000 | Nicotinamide | 50 mg |
| EPN0590000 | Nicotine - Reference Spectrum | unit |
| EPN0590200 | Nicotine ditartrate | 120 mg |
| EPY0001023 | Nicotine for system suitability | 1.25 mg |
| EPN0700000 | Nicotinic acid | 100 mg |
| EPN0750000 | Nifedipine | 50 mg |
| EPN0750010 | Nifedipine impurity A Dimethyl 2,6-dimethyl-4-(2-nitrophenyl) pyridine-3,5-dicarboxylate | 20 mg |
| EPN0750015 | Nifedipine impurity B Dimethyl 2,6-dimethyl-4-(2-nitrosophenyl) pyridine-3,5-dicarboxylate | 20 mg |
| EPY0000824 | Niflumic acid | 10 mg |
| EPY0000825 | Niflumic acid impurity A 2-chloropyridine-3-carboxylic acid | 10 mg |
| EPY0000826 | Niflumic acid impurity B 2-hydroxy-N-(3-(trifluoromethyl)phenyl)pyridine-3-carboxamide | 10 mg |
| EPY0000827 | Niflumic acid impurity E 6-((3-(trifluoromethyl)phenyl)amino)pyridine-3-carboxylic acid | 15 mg |
| EPY0000836 | Nifuroxazide | 10 mg |
| EPN0800000 | Nikethamide | 1 mL |
| EPY0000829 | Nilutamide | 110 mg |
| EPY0000894 | Nilutamide impurity B 4-nitro-3-(trifluoromethyl)aniline | 5 mg |
| EPN0845000 | Nimesulide | 100 mg |
| EPN0845008 | Nimesulide impurity D 4-nitro-2-phenoxyaniline | 0.004 mg |
| EPN0850000 | Nimodipine | 50 mg |
| EPN0850010 | Nimodipine impurity A 2-methoxyethyl 1-methylethyl 2,6-dimethyl-4-(3-nitrophenyl) pyridine-3,5-dicarboxylate | 1 mL |
| EPN0900000 | Nitrazepam Controlled Substance | 100 mg |
| EPN0900010 | Nitrazepam impurity A 3-amino-6-nitro-4-phenylquinol-2-one | 25 mg |
| EPN0905000 | Nitrendipine | 60 mg |
| EPN0905005 | Nitrendipine impurity A ethyl methyl-2,6-dimethyl-4-(3-nitrophenyl) pyridine-3,5-dicarboxylate; (nitrophenylpyridine analogue) | 30 mg |
| EPN0930000 | Nitric oxide - Reference Spectrum | unit |
| EPN0950000 | Nitrofural | 100 mg |
| EPN1000000 | Nitrosotriaminopyrimidine | 50 mg |
| EPN1090000 | Nizatidine | 250 mg |
| EPN1090060 | Nizatidine impurity F (EZ)N ¹ ,N ¹ [thiazole-2,4-diylbis(methylenesulphanediyethylene)] bis(N ¹ -methyl-2-nitroethene-1,1-diamine) | 10 mg |
| EPN1080000 | Nomegestrol acetate | 100 mg |
| EPN1080005 | Nomegestrol acetate impurity A 6- α -methyl-3,20-dioxo-19-norpregn-4-en-17-yl acetate | 50 mg |
| EPY0000670 | Nonivamide | 10 mg |
| EPY0000755 | Nonoxinol 9 | 10 mg |
| EPN1100000 | Noradrenaline tartrate | 200 mg |

| Code | Product | Unit |
|-----------------------|---|-----------|
| EPY0000681 | Noradrenaline impurity D 4[(1R)-2-amino-1-methoxyethyl]benzene-1,2-diol (Noradrenaline methyl ether) | 15 mg |
| EPY0000682 | Noradrenaline impurity E 2-chloro-1-(3,4-dihydroxyphenyl)ethanone | 10 mg |
| EPY0000686 | Noradrenaline impurity F N-benzyl-1-phenylmethanamine | 10 mg |
| EPN1130000 | Norcyclobenzaprine | 25 mg |
| EPN1140000 | Nordazepam Controlled Substance Dipotassium clorazepate impurity B | 50 mg |
| EPN1200000 | Norethisterone | 100 mg |
| EPN1225000 | Norethisterone acetate | 100 mg |
| EPY0000522 | Norethisterone for system suitability | 10 mg |
| EPN1230000 | Norfloxacin | 50 mg |
| EPN1230010 | Norfloxacin impurity A 7-chloro-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 20 mg |
| EPY0001015 | Norfloxacin for system suitability | 8 mg |
| EPY0000724 | Norgestimate | 10 mg |
| EPY0000725 | Norgestimate for system suitability | 5 mg |
| EPN1250000 | Norgestrel | 30 mg |
| EPN1279000 | Norpseudoephedrine hydrochloride Controlled Substance | 50 mg |
| New EPY0001296 | Nortriptyline for system suitability | 20 mg |
| EPN1280000 | Nortriptyline hydrochloride | 10 mg |
| EPN1300000 | Noscapine | 100 mg |
| EPN1400000 | Nystatin | 100 mg |
| EPO0100900 | Octoxinol 10 | 300 mg |
| EPY0000368 | Octyl gallate | 30 mg |
| EPO0101000 | Octyldodecanol | 400 mg |
| EPO0120000 | Ofloxacin | 50 mg |
| EPO0120010 | Ofloxacin impurity A (RS)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de][1,4]benzoxazine-6-carboxylic acid (FPA) | 20 mg |
| EPO0120050 | Ofloxacin impurity E (RS)-9-fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de] [1,4]benzoxazine-6-carboxylic acid | 20 mg |
| EPY0000805 | Oleuropein | 20 mg |
| EPO0146000 | Olsalazine sodium | 60 mg |
| EPO0146010 | Olsalazine sodium for performance test | 60 mg |
| EPO0150000 | Omeprazole | 50 mg |
| EPY0001043 | Omeprazole magnesium | 10 mg |
| EPY0001042 | Omeprazole for peak identification | 10 mg |
| EPO0151000 | Omeprazole impurity D Omeprazole sulphone | 5 mg |
| EPY0000218 | Ondansetron hydrochloride dihydrate | 200 mg |
| EPY0000197 | Ondansetron for LC system suitability | 10 mg |
| EPY0000196 | Ondansetron for TLC system suitability | 30 mg |
| EPY0000195 | Ondansetron impurity D 9-methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one | 10 mg |
| New EPY0001125 | Orbifloxacin | 200 mg |
| New EPY0001147 | Orbifloxacin impurity mixture | 0.0008 mg |
| EPO0180000 | Orciprenaline sulphate | 100 mg |
| EPY0000895 | Orciprenaline for system suitability | 5 mg |
| EPY0000101 | Orphenadrine citrate | 100 mg |
| EPY0000100 | Orphenadrine hydrochloride | 100 mg |
| New EPY0001181 | Orphenadrine for peak identification | 0.42 mg |

European Pharmacopoeia

| Code | Product | Unit |
|------------|--|----------|
| EPY0000102 | Orphenadrine impurity E (RS)-N,N-dimethyl-2-[(3-methylphenyl)phenylmethoxy]ethanamine (meta-methylbenzyl isomer) | 30 mg |
| EPO2020000 | Ouabain | 150 mg |
| EPY0000638 | Oxacillin sodium monohydrate | 110 mg |
| EPY0000560 | Oxacillin for peak identification | 10 mg |
| EPY0000271 | Oxaliplatin | 250 mg |
| EPY0000272 | Oxaliplatin impurity B (SP-4-2)-diaqua[(1R,2R)-cyclohexane-1,2-diamine-kN,kN']platinum (diaquodiaminocyclohexaneplatinum) | 25 mg |
| EPY0000273 | Oxaliplatin impurity C (OC-6-33)-[(1R,2R)-cyclohexane-1,2-diamine-kN,kN'] [ethanedioato(2-)- kO ¹ ,kO ²]dihydroxyplatinum | 15 mg |
| EPY0000274 | Oxaliplatin impurity D (SP-4-2)-[(1S,2S)-cyclohexane-1,2-diamine-kN,kN'] [ethanedioato(2-)- kO ¹ ,kO ²]platinum (S,S-enantiomer of oxaliplatin) | 10 mg |
| EPO2225000 | Oxazepam Controlled Substance | 50 mg |
| EPY0000543 | Oxazepam for peak identification | 0.008 mg |
| EPY0000350 | Oxeladin hydrogen citrate | 50 mg |
| EPY0000404 | Oxeladin impurity C 2-(diethylamino)ethyl 2-ethyl-2-phenylbutanoate | 10 mg |
| EPY0000390 | Oxeladin impurity D 2-(2-diethylaminoethoxy)ethyl 2-phenyl-butyrate dihydrogen citrate | 20 mg |
| EPO2225800 | Oxfendazole for veterinary use | 50 mg |
| EPY0000224 | Oxfendazole impurity B methyl[5-(phenylsulphonyl)-1H-benzimidazole-2-yl]carbamate | 10 mg |
| EPY0000225 | Oxfendazole with impurity D | 10 mg |
| EPY0000709 | Oxitropium bromide | 50 mg |
| EPY0000715 | Oxitropium bromide impurity B (1R,2R,4S,5S,7s)-7-[[[(2S)-3-hydroxy-2-phenylpropanoyl]oxy]-9,9-dimethyl-3-oxa- 9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane (methylhyoscyne) | 15 mg |
| EPY0000713 | Oxitropium bromide impurity D (1R,2R,4S,5S,7s,9r)-9-ethyl-9-methyl-7-[(2-phenylprop-2-enoyl)oxy]-3-oxa- 9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane (apo-N-ethylhyoscyne) | 10 mg |
| EPO2400000 | Oxolinic acid | 50 mg |
| EPO2400005 | Oxolinic acid impurity A 8-hydroxy-1,3-dioxolo[4,5-g]quinoline-7-carboxylic acid | 20 mg |
| EPO2400010 | Oxolinic acid impurity B ethyl 5-ethyl-8-oxo-5,8-dihydro-1,3-dioxolo[4,5-g]quinoline-7-carboxylate | 20 mg |
| EPO2500000 | Oxprenolol hydrochloride | 50 mg |
| EPO2600000 | Oxibendazole | 100 mg |
| EPO2700000 | Oxybuprocaine hydrochloride | 150 mg |
| EPO2880000 | Oxybutynin hydrochloride | 150 mg |
| EPO2880005 | Oxybutynin impurity A 4-(diethylamino)but-2-ynyl(RS)-2-(cyclohex-3-enyl)-2-cyclohexyl-2-hydroxyacetate | 10 mg |
| EPY0000492 | Oxycodone hydrochloride Controlled Substance | 100 mg |
| EPY0000453 | Oxycodone impurity D 7,8-didehydro-4,5 alpha-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one (14-hydroxycodeinone) | 25 mg |
| EPO2900000 | Oxymetazoline hydrochloride | 80 mg |
| EPY0001044 | Oxymetazoline impurity A N-(2-aminoethyl)-2-[4-(1,1-dimethylethyl)-3-hydroxy-2,6-dimethylphenyl]acetamide | 10 mg |
| EPO4000000 | Oxytetracycline | 100 mg |
| EPO5000000 | Oxytetracycline hydrochloride | 20 mg |
| EPO7000000 | Oxytocin | 1 mg |
| EPO7700000 | Oxytocin/Desmopressin validation mixture about 0.1 mg oxytocin + 0.1 mg desmopressin per vial | 0.2 mg |
| EPY0000698 | Paclitaxel | 40 mg |

| Code | Product | Unit |
|------------|--|----------|
| EPY0000699 | Paclitaxel impurity C N-debenzoyl-N-hexanoylpaclitaxel | 5 mg |
| EPY0000700 | Paclitaxel natural for peak identification | 10 mg |
| EPY0000719 | Paclitaxel semi-synthetic for peak identification | 10 mg |
| EPY0000739 | Paclitaxel semi-synthetic for system suitability | 1 mg |
| EPP0090000 | Palmitic acid | 100 mg |
| EPY0000524 | Pamidronate disodium pentahydrate | 10 mg |
| EPP0100000 | Pancreas powder (amylase and lipase) BRP | 2000 mg |
| EPP0200000 | Pancreas powder (protease) BRP | 2000 mg |
| EPP0250000 | Pancuronium bromide Vecuronium impurity B | 20 mg |
| EPY0000577 | Pancuronium bromide for system suitability | 20 mg |
| EPY0000835 | Pantoprazole sodium sesquihydrate | 20 mg |
| EPY0001001 | Pantoprazole for system suitability | 0.503 mg |
| EPP0270000 | Papaverine hydrochloride | 25 mg |
| EPP0300000 | Paracetamol | 50 mg |
| EPY0000780 | Paraffin (hard) | 10 mg |
| EPY0000058 | Paraffin (liquid) - Reference Spectrum | unit |
| EPY0000913 | Paraffin (White soft) | 10 mg |
| EPY0000912 | Paraffin (Yellow soft) | 10 mg |
| EPP0305000 | Parnaparin sodium | 250 mg |
| EPY0000578 | Paroxetine hydrochloride (anhydrous) | 100 mg |
| EPY0000281 | Paroxetine hydrochloride hemihydrate | 200 mg |
| EPY0000233 | Paroxetine impurity A (3S,4R)-3-[[1,3-benzodioxol-5-yloxy]methyl]-4-phenylpiperidine (desfluoroparoxetine) | 15 mg |
| EPY0000579 | Paroxetine hydrochloride (anhydrous) impurity C (3S,4R)-3-[[1,3-benzodioxol-5-yloxy]methyl]-1-benzyl-4-(4-fluorophenyl)piperidine (N-benzylparoxetine) | 10 mg |
| EPY0000256 | Paroxetine impurity D (3R,4S)-3-[[1,3-benzodioxol-5-yloxy]methyl]-4-(4-fluorophenyl)piperidine ((+)-trans-paroxetine) | 5 mg |
| EPY0000580 | Paroxetine impurity E (3RS,4RS)-3-[[1,3-benzodioxol-5-yloxy]methyl]-4-(4-fluorophenyl)piperidine (cis-paroxetine) | 5 mg |
| EPY0000581 | Paroxetine hydrochloride (anhydrous) impurity H [(3S,4R)-1-benzyl-4-(4-fluorophenyl)piperidin-3-yl]methanol | 10 mg |
| EPY0000630 | Paroxetine for system suitability | 5 mg |
| EPP0309000 | Pefloxacin mesilate dihydrate | 200 mg |
| EPP0309020 | Pefloxacin impurity B 1-ethyl-6-chloro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (chlorinated homologue of pefloxacin) | 10 mg |
| EPP0309030 | Pefloxacin impurity C 1-ethyl-6-fluoro-5-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (isopefloxacin) | 0.01 mg |
| EPP0307000 | Penbutolol sulphate | 100 mg |
| EPP0307005 | Penbutolol impurity A (2S)-1-[2-(cyclopent-1-enyl)phenoxy]-3-[(1,1-dimethylethyl)amino]propan-2-ol | 20 mg |
| EPP0310000 | Penicillamine | 100 mg |
| EPP0320000 | Penicillamine disulphide 3,3-(disulphanediyl)bis[(2)-2-amino-3-methylbutanoic]acid | 100 mg |
| EPP0400100 | Pentaerythryl tetranitrate diluted | 600 mg |
| EPP0405000 | Pentamidine diisetonate | 30 mg |
| EPP0405500 | Pentazocine - Reference Spectrum | unit |
| EPP0405510 | Pentazocine hydrochloride - Reference Spectrum | unit |
| EPY0000417 | Pentazocine lactate - Reference Spectrum | unit |
| EPY0001051 | Pentetate sodium calcium | 100 mg |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|--|-----------|
| EPP0500000 | Pentobarbital Controlled Substance | 500 mg |
| EPP0510000 | Pentoxifylline | 100 mg |
| EPY0000076 | Pentoxyverine hydrogen citrate - Reference Spectrum | unit |
| EPY0000098 | Pentoxyverine impurity A 1-phenylcyclopentanecarboxylic acid | 10 mg |
| EPY0000099 | Pentoxyverine impurity B 2-(diethylamino)ethyl-1-phenylcyclopentanecarboxylate (caramiphen) | 10 mg |
| EPP0525000 | Pepsin powder | 2000 mg |
| EPY0000010 | Pergolide mesilate | 150 mg |
| EPY0000237 | Perindopril impurity A (2S,3aS,7aS)-octahydro-1Hindole-2-carboxylic acid | 10 mg |
| EPY0000207 | Perindopril for stereochemical purity | 40 mg |
| EPY0000238 | Perindopril tert-butylamine | 40 mg |
| EPY0000771 | Perindopril for peak identification | 5 mg |
| EPP0550000 | Perphenazine | 100 mg |
| EPY0001045 | Perphenazine for system suitability | 5 mg |
| EPY0000021 | Pertussis toxin BRP | 2x0.05 mg |
| EPP0600000 | Pethidine hydrochloride - Reference Spectrum | unit |
| EPP0600002 | Pethidine impurity A 1-methyl-4-phenylpiperidine (MPP) | 20 mg |
| EPP0800000 | Phenazone | 20 mg |
| New EPY0001138 | Phenazone impurity A 5-methyl-2-phenyl-2,4-dihydro-3-pyrazol-3-one | 20 mg |
| EPP0850000 | Pheniramine maleate | 250 mg |
| EPP0900000 | Phenobarbital Controlled Substance | 250 mg |
| EPP0950000 | Phenoxyethanol | 2 mL |
| EPP1000000 | Phenoxymethylpenicillin | 250 mg |
| EPP1100000 | Phenoxymethylpenicillin potassium | 250 mg |
| EPP1109000 | Phentolamine mesilate - Reference Spectrum | unit |
| EPP1150000 | Phenylalanine | 60 mg |
| EPP1200000 | Phenylbutazone | 100 mg |
| EPY0000147 | Phenylbutazone impurity B (4-butyl-4-hydroxy-1,2-diphenyl-3,5)pyrazolidinedione | 20 mg |
| EPP1240000 | Phenylephrine | 60 mg |
| EPP1250000 | Phenylephrine hydrochloride | 50 mg |
| EPY0000683 | Phenylephrine hydrochloride for peak identification | 2 mg |
| EPY0000229 | Phenylmercuric acetate - Reference Spectrum | unit |
| EPP1255100 | Phenylmercuric borate - Reference Spectrum | unit |
| EPP1260000 | Phenylpropanolamine hydrochloride Drug Precursor | 50 mg |
| EPP1290000 | Phenytoin | 100 mg |
| New EPY0001167 | Phenytoin for system suitability | 20 mg |
| EPP1300000 | Phenytoin sodium | 250 mg |
| EPY0000493 | Phloroglucinol (anhydrous) | 210 mg |
| EPY0000761 | Pholcodine Controlled Substance | 10 mg |
| EPY0000798 | Pholcodine for peak identification Controlled Substance | 10 mg |
| EPY0000766 | Phthalic acid benzene-1,2-dicarboxylic acid | 20 mg |
| EPP1500000 | Phthalylsulfathiazole | 100 mg |
| EPP1600000 | Physostigmine salicylate | 100 mg |
| EPP1605000 | Physostigmine sulphate | 100 mg |
| EPP1609000 | Phytomenadione | 150 mg |
| EPP1609010 | trans-Epoxyphytomenadione | 10 mg |
| EPY0001104 | Picosulfate for system suitability | 0.5 mg |

| Code | Product | Unit |
|------------|--|--------|
| EPP1645000 | Picotamide monohydrate | 125 mg |
| EPP1645005 | Picotamide impurity A 4-methoxybenzene-1,3-dicarboxylic acid | 25 mg |
| EPY0000124 | Pidolate impurity B (2S)-2-[[[(2S)-5-oxopyrrolidin-2-yl]carbonyl]amino]pentanedioic acid | 60 mg |
| EPY0000123 | Pidolic acid | 125 mg |
| EPP1650000 | Pilocarpine hydrochloride | 50 mg |
| EPP1700000 | Pilocarpine nitrate | 50 mg |
| EPY0000106 | Pilocarpine nitrate for system suitability | 20 mg |
| EPY0000525 | Pimobendan | 10 mg |
| EPY0000401 | Pimobendan for system suitability | 0.1 mg |
| EPP1750000 | Pimozide | 150 mg |
| EPP1800000 | Pindolol | 100 mg |
| EPY0000061 | Pipemicidic acid trihydrate - Reference Spectrum | unit |
| EPP1890000 | Piperacillin | 100 mg |
| EPP1900000 | Piperazine adipate | 250 mg |
| EPP2000000 | Piperazine citrate | 250 mg |
| EPP2100000 | Piperazine hydrate | 250 mg |
| EPY0000288 | Piracetam | 120 mg |
| EPY0000038 | Pirenzepine dihydrochloride monohydrate | 250 mg |
| EPP2120000 | Piretanide | 100 mg |
| EPP2120002 | Piretanide impurity A 4-phenoxy-3(1H-pyrrol-1-yl)-5-sulphamoylbenzoic acid | 20 mg |
| EPP2130000 | Piroxicam | 100 mg |
| EPP2130100 | Piroxicam for system suitability | 10 mg |
| EPP2150000 | Pivampicillin | 50 mg |
| EPP2152000 | Pivmecillinam hydrochloride | 100 mg |
| EPP2152015 | Pivmecillinam impurity C methylene 2,2-dimethylpropanoate (2RS,4S)-2-[[[(hexahydro-1H-azepin-1-yl)methylene]amino]methyl]-5,5-dimethylthiazolidin-4-carboxylate | 10 mg |
| EPP2155001 | Plastic additive 01 (2RS)-2-ethylhexylbenzene-1,2-dicarboxylate | 2 mL |
| EPP2155003 | Plastic additive 03 N,N'-ethylenedialcanamide | 100 mg |
| EPE0800000 | Plastic additive 04 Epoxidised soya oil | 500 mg |
| EPP2155005 | Plastic additive 05 Epoxidised linseed oil | 500 mg |
| EPP2155008 | Plastic additive 08 Ethylene bis [3,3-bis[(3-(1,1-dimethylethyl)-4-hydroxyphenyl)]bitanoate] | 500 mg |
| EPP2155009 | Plastic additive 09 pentaerythrityl tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate] | 250 mg |
| EPP2155010 | Plastic additive 10 4,4',4''-(2,4,6-trimethylbenzene-1,3,5-triyltrismethylene)-trio[2,6-bis(1,1-dimethylethyl)phenol] | 250 mg |
| EPP2155011 | Plastic additive 11 Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate | 500 mg |
| EPP2155012 | Plastic additive 12 Tris(2,4-di-1,1-dimethylethylphenyl)phosphite R | 250 mg |
| EPP2155013 | Plastic additive 13 1,3,5-tris(3,5-di-1,1-dimethylethyl-4-hydroxybenzyl)-1H,3H,5H-1,3,5-triazine-2,4,6-trione | 250 mg |
| EPP2155014 | Plastic additive 14 2,2'-Di(octadecyloxy)5,5'-spirobi(1,3,2,-dioxaphosphorinane)R | 250 mg |
| EPP2155015 | Plastic additive 15 Dioctadecyl disulphide | 500 mg |
| EPP2155016 | Plastic additive 16 Didodecyl 3,3'-thiodipropionate R | 250 mg |

European Pharmacopoeia

| Code | Product | Unit |
|-----------------------|--|----------|
| EPP2155017 | Plastic additive 17 Dioctadecyl 3,3'-thiodipropionate R | 250 mg |
| EPP2155018 | Plastic additive 18 | 100 mg |
| EPO0140000 | Plastic additive 20 Oleamide R | 100 mg |
| EPE1260000 | Plastic additive 21 Erucamide R | 100 mg |
| EPP2155022 | Plastic additive 22 Copolymer of dimethyl butanedioate and 1-(2-hydroxyethyl)-2,2,6,6-tetramethylpiperidin-4-ol Synonyms: copolymer of dimethyl succinate and (4-hydroxy-2,2,6,6-tetramethylpiperidin-1-yl)ethanol | 100 mg |
| EPP2155023 | Plastic additive 23 di(isooctyl)2,2'-[(dioctylstannylene)bis(thio)]diacetate containing about 27% of (tri(isooctyl)2,2',2''-[monooctylstannilydne]tris(thio)]triacetate. Tin-content of 15.4% | 200 mg |
| EPP2160000 | Poliomyelitis vaccine (inactivated) BRP | 5x0.5 mL |
| EPP2161000 | Poliomyelitis vaccine (oral) BRP | 5x1 mL |
| EPP2163920 | Poloxamer 124 | 30 mg |
| EPP2164009 | Poloxamer 188 | 100 mg |
| EPP2164020 | Poloxamer 237 | 100 mg |
| EPP2164021 | Poloxamer 338 | 100 mg |
| EPP2164030 | Poloxamer 407 | 100 mg |
| EPP2170000 | Polyacrylate - Reference Spectrum | unit |
| EPP2400000 | Polymyxin B sulphate | 25 mg |
| EPY0000355 | Polymyxin B sulphate for microbiological assay | 25 mg |
| EPY0000289 | Polysorbate 20 - Reference Spectrum | unit |
| EPY0000290 | Polysorbate 40 - Reference Spectrum | unit |
| EPY0000291 | Polysorbate 60 - Reference Spectrum | unit |
| EPY0000007 | Polysorbate 80 - Reference Spectrum | unit |
| EPY0000792 | Poly(vinyl acetate) dispersion 30% | 1500 mg |
| EPP2600000 | Poly(vinyl chloride) | 100 mg |
| EPP2649610 | Potassium clavulanate - Reference Spectrum | unit |
| New EPY0001168 | Potassium clavulanate impurity G | 5 mg |
| EPY0000315 | Potassium hydrogen aspartate hemihydrate | 50 mg |
| EPP2650000 | Potassium sorbate*) | 100 mg |
| EPP2660000 | Povidone | 50 mg |
| EPY0000466 | Povidone (iodinated) | 10 mg |
| New EPY0001266 | Pramipexole dihydrochloride monohydrate | 5 mg |
| New EPY0001267 | Pramipexole impurity D (6R)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine | 5 mg |
| New EPY0001187 | Pramipexole for system suitability | 15 mg |
| EPY0000215 | Pravastatin sodium - Reference Spectrum | unit |
| EPY0000223 | Pravastatin impurity A (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6R,8S,8aR)-6-hydroxy-2-methyl-8-[[[(2S)-2-methylbutanoyl]oxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid (6'-epipravastatin) | 0.1 mg |
| EPY0000204 | Pravastatin 1,1,3,3-tetramethylbutylamine | 30 mg |
| EPP2669000 | Prazepam Controlled Substance | 50 mg |
| EPP2670000 | Praziquantel | 150 mg |
| EPP2675000 | Praziquantel impurity A (11bRS)-2-benzoyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one | 10 mg |
| EPP2680000 | Prazosin hydrochloride | 50 mg |
| EPP2698000 | Prednicarbate | 100 mg |
| EPP2698060 | Prednicarbate impurity F 1,2-dihydroprednicarbate | 10 mg |
| EPP2700000 | Prednisolone | 150 mg |

| Code | Product | Unit |
|------------|--|-----------|
| EPP2800000 | Prednisolone acetate | 120 mg |
| EPY0000582 | Prednisolone acetate for peak identification | 10 mg |
| EPP2804000 | Prednisolone hexanoate | 10 mg |
| EPP2805000 | Prednisolone pivalate | 100 mg |
| EPP2810000 | Prednisolone sodium phosphate | 100 mg |
| EPP2900000 | Prednisone | 100 mg |
| EPP2920000 | Pregnenolone isobutyrate | 150 mg |
| EPY0000263 | Prekallikrein activator in albumin BRP | 3x1 mL |
| EPP2939000 | Prilocaine | 150 mg |
| EPP2939060 | Prilocaine hydrochloride | 100 mg |
| EPP2939025 | Prilocaine impurity E (RS)-N-(methylphenyl)-2-(propylamino)propanamide | 25 mg |
| EPP2940000 | Primaquine diphosphate | 500 mg |
| EPP2950000 | Primidone | 150 mg |
| EPY0000369 | Primidone for peak identification | 5 mg |
| EPP3000000 | Probenecid | 100 mg |
| EPP3050000 | Procainamide hydrochloride | 100 mg |
| EPP3090000 | Procaine benzylpenicillin | 250 mg |
| EPP3100000 | Procaine hydrochloride | 100 mg |
| EPP3200000 | Prochlorperazine maleate | 100 mg |
| EPP3300000 | Progesterone | 50 mg |
| EPY0000148 | Progesterone impurity C (20R)-20-hydroxypregn-4-en-3-one | 10 mg |
| EPY0000179 | Proguanil hydrochloride - Reference Spectrum | unit |
| EPY0000181 | Proguanil impurity C 1,5-bis(4-chlorophenyl)biguanide | 10 mg |
| EPY0000182 | Proguanil impurity D 1,5-bis(1-methylethyl)biguanide | 10 mg |
| EPP3350000 | Proline | 60 mg |
| EPP3390000 | Promazine hydrochloride | 100 mg |
| EPP3400000 | Promethazine hydrochloride | 50 mg |
| EPY0000769 | Promethazine impurity D (2RS)-N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine S-oxide | 10 mg |
| EPY0000797 | Promethazine for peak identification | 10 mg |
| EPP3490000 | Propacetamol hydrochloride - Reference Spectrum | unit |
| EPY0000455 | Propafenone hydrochloride | 10 mg |
| EPY0000456 | Propafenone impurity B 2E)-1-[2-[(2RS)-2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylprop-2-en-1-one | 10 mg |
| EPY0000278 | Propanol - Reference Spectrum | unit |
| EPY0000016 | Propofol | 290 mg |
| EPY0000017 | Propofol for peak identification | 0.1 mL |
| EPY0000018 | Propofol impurity J 2,6-bis (1-methylethyl)-1,4-benzoquinone | 20 mg |
| EPP3500000 | Propranolol hydrochloride | 30 mg |
| EPP3600000 | Propranolol hydrochloride for performance test | 20 mg |
| EPY0000318 | Propylene glycol dilaurate | 100 mg |
| EPY0000319 | Propylene glycol monolaurate | 100 mg |
| EPP3640000 | Propyl gallate | 50 mg |
| EPP3650000 | Propyl parahydroxybenzoate | 100 mg |
| EPP3700000 | Propylthiouracil | 100 mg |
| EPP3750000 | Propyphenazone | 200 mg |
| EPP3760000 | Protirelin | 2x5.03 mg |
| EPP3760020 | D-His Protirelin | 0.1 mg |

European Pharmacopoeia

| | Code | Product | Unit |
|------------|------------|--|------------|
| | EPP3800000 | Proxiphylline | 100 mg |
| | EPP3850000 | Pseudoephedrine hydrochloride Drug Precursor | 100 mg |
| | EPY0000387 | Pseudoisoeugenyl 2-methylbutyrate for peak identification | 100 mg |
| | EPP3900000 | Purpureaglycoside A | 25 mg |
| | EPP4000000 | Purpureaglycoside B | 25 mg |
| | EPY0000402 | Pyrantel embonate | 10 mg |
| | EPY0000403 | Pyrantel impurity A 1-methyl-2-[(Z)-2-(thiophen-2-yl)ethenyl]-1,4,5,6-tetrahydropyrimidine | 20 mg |
| | EPP4050000 | Pyrazinamide | 30 mg |
| | EPP4099900 | Pyridostigmine bromide | 50 mg |
| | EPP4099910 | Pyridostigmine impurity A pyridin-3-yl-dimethylcarbamate | 20 mg |
| | EPP4100000 | Pyridoxine hydrochloride | 100 mg |
| New | EPY0001226 | Pyridoxine impurity A 6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol | 5 mg |
| | EPP4200000 | Pyrimethamine | 250 mg |
| | EPY0000659 | Pyrrolidone | 20 mg |
| | EPY0001009 | Quercetin dihydrate | 20 mg |
| | EPQ0100000 | Quinidine sulphate | 300 mg |
| | EPQ0200000 | Quinine sulphate | 300 mg |
| | EPR0100000 | Rabies vaccine (inactivated) for veterinary use BRP | 3x86 mg |
| | EPY0000896 | Racecadotril | 110 mg |
| | EPY0000897 | Racecadotril impurity A Ethanethioic acid | 1 mL |
| | EPY0000898 | Racecadotril impurity G benzyl[[[(2R)-2-benzyl-3-sulfanylpropanoyl]amino]acetate | 10 mg |
| | EPY0000902 | Racecadotril for peak identification | 5 mg |
| New | EPY0001134 | Raloxifene hydrochloride | 110 mg |
| New | EPY0001135 | Raloxifene hydrochloride for peak identification | 10 mg |
| | EPR0145000 | Ramipril | 20 mg |
| | EPR0145005 | Ramipril impurity A (2S,3aS,6aS)-1-[(S)-2-[[[(S)-1-(methoxycarbonyl)-3-phenylpropyl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (ramipril methylester) | 10 mg |
| | EPR0145010 | Ramipril impurity B (2S,3aS,6aS)-1-[(S)-2-[[[(S)-1-[(methylethoxy)carbonyl]-3-phenylpropyl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (ramipril isopropyl ester) | 10 mg |
| | EPR0145015 | Ramipril impurity C (2S,3aS,6aS)-1-[(S)-2-[[[(S)-1-(ethoxycarbonyl)-3-cyclohexylpropyl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (hexahydroramipril) | 10 mg |
| | EPR0145020 | Ramipril impurity D ethyl(2S)-2-[(3S,5aS,8aS,9aS)-3-methyl-1,4-dioxodecahydro-1H-cyclopenta[e]pyrrolo[1,2a]pyrazin-2-yl]-4-phenylbutanoate (ramipril diketopiperazine) | 10 mg |
| | EPR0150000 | Ranitidine hydrochloride | 100 mg |
| | EPY0000416 | Ranitidine impurity J 1,1'-N-[methylenebis(sulphanediylethylene)]bis (N'-methyl-2-nitroethene-1,1-diamine) | 0.00025 mg |
| | EPY0000411 | Ranitidine for system suitability | 20 mg |
| | EPY0000457 | Repaglinide | 20 mg |
| | EPY0000458 | Repaglinide for system suitability | 6 mg |
| | EPY0000459 | Repaglinide impurity E 2-ethoxy-4-[2-[[[(1R)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid | 5 mg |
| | EPR0200000 | Reserpine | 100 mg |
| | EPR0250000 | Residual solvents solution class I | 1500 mg |

| Code | Product | Unit |
|-----------------------|--|---------|
| EPY0000767 | Resorcinol | 20 mg |
| EPR0300000 | Retinol acetate | 1000 mg |
| EPR0290000 | Retinol ester | 100 mg |
| EPR0500500 | Reviparin sodium | 250 mg |
| EPY0000377 | Ribavirin | 100 mg |
| EPY0000353 | Ribavirin for system suitability | 1 mg |
| EPR0600000 | Riboflavin (Vitamine B ₂) | 100 mg |
| EPY0000757 | Riboflavin for peak identification | 0.1 mg |
| EPR0630000 | Riboflavine sodium phosphate | 250 mg |
| EPY0000662 | Ribonucleic acid | 100 mg |
| EPY0000149 | Rifabutin | 150 mg |
| EPY0000184 | Rifabutin impurity A 1-(2-methylpropyl)piperidin-4-one | 20 mg |
| EPR0700000 | Rifampicin | 500 mg |
| EPR0800000 | Rifampicin quinone | 100 mg |
| EPR0900000 | Rifamycin B | 50 mg |
| EPR0950000 | Rifamycin S | 50 mg |
| EPR1000000 | Rifamycin sodium | 300mg |
| New EPY0001074 | Rifaximin | 160 mg |
| EPY0001075 | Rifaximin for system suitability | 10 mg |
| EPY0000250 | Rilmenidine dihydrogenophosphate - Reference Spectrum | unit |
| EPY0000187 | Rilmenidine for system suitability | 30 mg |
| EPR1000600 | Risperidone | 50 mg |
| EPY0000370 | Risperidone for system suitability | 20 mg |
| EPR1300000 | RK 13 cells cell lines (kidney,rabbit) titration of live measles, mumps and rubella vaccines | 2x1 mL |
| EPY0000714 | Ritonavir | 80 mg |
| EPY0000706 | Ritonavir for peak identification | 10 mg |
| EPY0000594 | Rocuronium bromide - Reference Spectrum | unit |
| EPY0000527 | Rocuronium for peak identification | 10 mg |
| EPY0000742 | Ropivacaine hydrochloride monohydrate | 10 mg |
| EPY0000743 | Ropivacaine impurity G (+)-(2R)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide ((R)-ropivacaine) | 5 mg |
| EPY0000786 | Rosmarinic acid | 40 mg |
| EPR1500000 | Roxithromycin | 125 mg |
| EPY0000220 | Roxithromycin for system suitability | 5 mg |
| EPR2000000 | Rubella vaccine (live) BRP | 5x18 mg |
| EPY0000494 | Ruscogenins | 10 mg |
| EPY0000105 | Rutoside trihydrate | 100 mg |
| EPS0040000 | Saccharin | 30 mg |
| EPS0050000 | Saccharin Sodium | 50 mg |
| EPS0100000 | Salbutamol | 50 mg |
| EPY0000030 | Salbutamol impurity B (1RS)-2-[(1,1-dimethylethyl)amino]-1-(4-hydroxyphenyl)ethanol | 5 mg |
| EPY0000071 | Salbutamol impurity D 5-[(1RS)-2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-hydroxybenzaldehyde | 5 mg |
| EPY0000031 | Salbutamol impurity F 1,1[oxybis[methylene(4-hydroxy-1,3-phenylene)]]bis [2-[(1,1-dimethylethyl)amino]ethanol] | 5 mg |
| EPY0000034 | Salbutamol impurity G 2-[benzyl(1,1-dimethylethyl)amino]-1-[4-hydroxy-3-hydroxymethyl]phenyl]ethanone | 5 mg |

European Pharmacopoeia

| | Code | Product | Unit |
|------------|------------|---|-----------|
| | EPY0000032 | Salbutamol impurity I (1RS)-2-[(1,1-dimethylethyl)amino]-1-[3-(hydroxymethyl)-4-benzyloxyphenyl] ethanol | 0.006 mg |
| New | EPY0001186 | Salbutamol impurity J 2-[(1,1-dimethylethyl)amino]-1-[4-hydroxy-3-(hydroxymethyl)phenyl]ethanone (salbutamone) | Each |
| | EPS0150000 | Salbutamol sulphate | 50 mg |
| | EPY0000669 | Salicin | 50 mg |
| | EPS0200000 | Salicylic acid | 100 mg |
| | EPY0000405 | Salicylic acid impurity B 4-hydroxyisophthalic acid | 10 mg |
| | EPY0000422 | Salmeterol xinafoate | 40 mg |
| | EPY0000423 | Salmeterol xinafoate for system suitability | 25 mg |
| | EPY0001052 | Santonin | 20 mg |
| | EPY0001049 | Saquinavir mesilate | 70 mg |
| | EPY0001056 | Saquinavir for system suitability | 0.3033 mg |
| | EPY0000814 | Selamectin | 100 mg |
| | EPY0000815 | Selamectin for system suitability | 5 mg |
| | EPS0360000 | Selegiline hydrochloride | 50 mg |
| | EPS0360090 | (RS)-Selegiline hydrochloride | 25 mg |
| | EPS0400000 | Senna extract | 50 mg |
| | EPS0450000 | Serine | 50 mg |
| | EPS0460000 | Sertaconazole nitrate | 125 mg |
| | EPY0000828 | Sertraline hydrochloride | 200 mg |
| | EPY0000866 | Sertraline for peak identification | 2.8 mg |
| | EPY0000867 | Sertraline for system suitability | 3.2 mg |
| | EPY0000371 | Sestamibi labelling kit | 22 uc |
| | EPY0001046 | Sevoflurane | 1 mL |
| | EPS0500000 | Silicone elastomer | 2000 mg |
| | EPS0600000 | Silicone oil | 1 mL |
| | EPS0650000 | Simvastatin | 100 mg |
| | EPY0001066 | Simvastatin for peak identification | 10 mg |
| | EPS0660000 | Sisomicin sulphate | 50 mg |
| | EPY0000014 | Sodium alendronate | 150 mg |
| | EPS0695000 | Sodium amidotrizoate | 125 mg |
| | EPY0000300 | Sodium aminosalicylate dihydrate - Reference Spectrum | unit |
| | EPY0000039 | Sodium ascorbate | 50 mg |
| | EPS0700000 | Sodium calcium edetate | 100 mg |
| | EPS0710000 | Sodium cetostearyl sulphate | 100 mg |
| | EPS0750000 | Sodium cromoglicate | 10 mg |
| | EPS0760000 | Sodium cyclamate | 100 mg |
| | EPS0765000 | Diclofenac sodium | 100 mg |
| | EPS0781000 | Sodium hyaluronate - Reference Spectrum | unit |
| | EPS0780000 | Sodium hyaluronate BRP | 300 mg |
| | EPY0000620 | Sodium laurilsulfate | 40 mg |
| | EPY0000808 | Sodium phenylbutyrate | 5 mg |
| | EPY0000809 | Sodium phenylbutyrate impurity C 4-cyclohexylbutanoic acid | 10 mg |
| | EPS0785000 | Sodium picosulphate | 100 mg |
| | EPY0000210 | Sodium polystyrene sulphonate - Reference Spectrum | unit |
| | EPY0000268 | Sodium propionate - Reference Spectrum | unit |
| | EPS0800000 | Sodium salicylate | 100 mg |
| | EPS0808000 | Sodium stearyl fumarate | 50 mg |
| | EPS0808060 | Sodium stearyl maleate | 10 mg |

| Code | Product | Unit |
|-----------------------|--|----------|
| EPS0900000 | Sodium taurocholate BRP | 10000 mg |
| EPS0930000 | Sodium valproate | 150 mg |
| EPS0945000 | Somatostatin | 2.45 mg |
| EPS0947000 | Somatropin | 35 mg |
| EPY0000711 | Somatropin/desamidomatropin resolution mixture | 33 mg |
| EPS0950000 | Sorbic acid | 10 mg |
| EPY0000385 | 1,4-Sorbitan | 50 mg |
| EPS1000000 | Sorbitol | 1200 mg |
| EPY0000114 | Sotalol hydrochloride | 25 mg |
| EPY0000115 | Sotalol impurity B N-[4-[[[(1-methylethyl)amino]acetyl]phenyl]methanesulphonamide | 20 mg |
| EPY0001011 | Spanish sage oil for peak identification | 250 mg |
| EPY0000597 | Spectinomycin hydrochloride | 100 mg |
| EPY0000549 | Spectinomycin for system suitability | 20 mg |
| EPY0000655 | Spectinomycin sulphate tetrahydrate | 10 mg |
| New EPY0001126 | Spike lavender oil | 400 µl |
| EPS1100000 | Spiramycin | 200 mg |
| EPY0000381 | Spirapril hydrochloride monohydrate | 60 mg |
| EPY0000332 | Spirapril for system suitability | 15 mg |
| EPS1200000 | Spironolactone | 100 mg |
| EPY0000185 | Squalane | 0.25 mL |
| EPY0001050 | St.John's wort standardised dry extract | 500 mg |
| EPY0001091 | Standardised artichoke leaf dry extract | 60 mg |
| EPS1250000 | Stanozolol | 125 mg |
| EPS1250010 | Stanozolol impurity A (5 α ,17 β)-17-hydroxy-17-methylandrostan-3-one | 10 mg |
| EPS1300000 | Starch BRP | 50000 mg |
| EPY0000408 | Stavudine | 100 mg |
| EPY0000421 | Stavudine for system suitability | 10 mg |
| EPS1340000 | Stearic acid Plastic additive 19 | 100 mg |
| EPS1350000 | Stearyl alcohol | 250 mg |
| New EPY0000868 | Streptokinase for system suitability | 30 µl |
| EPS1400000 | Streptomycin sulphate | 100 mg |
| EPS1500000 | Succinylsulfathiazole | 100 mg |
| EPS1600000 | Sucrose | 100 mg |
| EPS1608100 | Sufentanil - Reference Spectrum | unit |
| EPS1609000 | Sufentanil citrate - Reference Spectrum | unit |
| EPY0000529 | Sulbactam sodium | 10 mg |
| EPY0000528 | Sulbactam | 150 mg |
| EPY0000550 | Sulbactam for peak identification | 20 mg |
| EPS1700000 | Sulfacetamide sodium | 50 mg |
| EPS1800000 | Sulfadiazine | 100 mg |
| EPS1900000 | Sulfadimidine | 100 mg |
| EPS1950000 | Sulfadoxine | 50 mg |
| EPS1975000 | Sulfafurazole | 100 mg |
| EPS1975600 | Sulfaguanidine | 60 mg |
| EPS2000000 | Sulfamerazine | 100 mg |
| EPS2050000 | Sulfamethizole | 100 mg |
| EPS2100000 | Sulfamethoxazole | 50 mg |
| EPY0000412 | Sulfamethoxazole impurity A N-(4-(5-methyl)-isoxazol-3-ylsulphamoyl)phenylacetamide | 5 mg |

European Pharmacopoeia

| Code | Product | Unit |
|------------|---|------------|
| EPY0000413 | Sulfamethoxazole impurity F 4-amino-N-(3-methylisoxazol-5-yl)benzenesulphonamide | 5 mg |
| EPS2150000 | Sulfamethoxypyridazine | 50 mg |
| EPS2151000 | Sulfanilamide | 100 mg |
| EPS2159100 | Sulfapyridine | 20 mg |
| EPS2155000 | Sulfasalazine | 2 x 250 mg |
| EPS2155010 | Sulfasalazine derivative for resolution 2-hydroxy-5-[[4-[[[(6-methylpyridin-2-yl)amino]-sulfonyl]phenyl]azo]benzoic acid | 20 mg |
| EPS2158000 | Sulfathiazole | 100 mg |
| EPS2159000 | Sulfinpyrazone | 30 mg |
| EPS2159010 | Sulfinpyrazone impurity A 1,2-diphenyl-4-(2-phenylsulphonylethyl)pyrazolidine-3,5-dione | 20 mg |
| EPS2159015 | Sulfinpyrazone impurity B 1,2-diphenyl-4-(2-phenylthioethyl)pyrazolidine-3,5-dione | 20 mg |
| EPS2160000 | Sulfisomidine | 50 mg |
| EPS2180000 | Sulindac | 50 mg |
| EPS2190000 | Sulpiride | 100 mg |
| EPS2191000 | Sulpiride impurity A [(2RS)-1-ethylpyrrolidin-2-yl]methanamine | 20 mg |
| EPS2192000 | Sulpiride impurity B methyl 2-methoxy-5-sulphamoylbenzoate | 20 mg |
| EPY0000530 | Sultamicillin | 10 mg |
| EPY0000531 | Sultamicillin tosilate | 200 mg |
| EPY0000532 | Sultamicillin for peak identification | 10 mg |
| EPY0000022 | Sumatriptan succinate | 50 mg |
| EPY0000026 | Sumatriptan impurity mixture | 3 mg |
| EPY0000027 | Sumatriptan for system suitability | 2 mg |
| EPS2200000 | Suxamethonium chloride | 1000 mg |
| EPS2400000 | Suxibuzone | 50 mg |
| EPS2400004 | Suxibuzone impurity B (4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methyl ethyl butanedioate | 10 mg |
| EPS2400006 | Suxibuzone impurity C 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-1,2-dihydro-4H-pyrazole-3,5-dione | 10 mg |
| EPS5000001 | Swine erysipelas bacteria, serotyp 1 (for vaccines-vet.use) BRP | 1 mg |
| EPS5000002 | Swine erysipelas bacteria, serotyp 2 (for vaccines-vet.use) BRP | 1 mg |
| EPT0010000 | Talampicillin hydrochloride | 50 mg |
| EPT0014000 | Tamoxifen citrate | 80 mg |
| EPT0015000 | Tamoxifen citrate for performance test | 30 mg |
| EPY0000650 | Tamsulosin hydrochloride | 10 mg |
| EPY0000653 | Tamsulosin racemate | 10 mg |
| EPY0000651 | Tamsulosin impurity D 2-methoxy-5-[(2R)-2-[[2-(2-methoxyphenoxy)ethyl]amino]propyl]benzenesulfonamide | 10 mg |
| EPY0000652 | Tamsulosin impurity H (2R)-N-[2-(2-ethoxyphenoxy)ethyl]-1-(4-methoxyphenyl)propan-2-amine | 10 mg |
| EPY0001102 | Teicoplanin | 52 mg |
| EPY0001047 | Teicoplanin for identification | 40 mg |
| EPY0000648 | Telmisartan | 30 mg |
| EPY0000649 | Telmisartan for peak identification | 10 mg |
| EPY0001003 | Telmisartan for system suitability | 0.26 mg |
| EPT0040000 | Temazepam Controlled Substance | 50 mg |
| EPY0000344 | Temazepam impurity C (3RS)-7-chloro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl acetate Controlled Substance | 5 mg |

| Code | Product | Unit |
|-----------------------|--|-----------|
| EPY0000345 | Temazepam impurity D (3RS)-7-chloro-3-methoxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one Controlled Substance | 5 mg |
| EPY0000346 | Temazepam impurity F (5RS)-7-chloro-1-methyl-5-phenyl-4,5-dihydro-1H-1,4-benzodiazepine-2,3-dione | 5 mg |
| EPY0000347 | Temazepam impurity G (5RS)-7-chloro-1,4-methyl-5-phenyl-4,5-dihydro-1H-1,4-benzodiazepine-2,3-dione | 5 mg |
| EPT0040800 | Tenoxicam | 100 mg |
| New EPY0001114 | Tenoxicam impurity mixture | 0.0042 mg |
| EPY0000621 | Terazosin hydrochloride dihydrate | 40 mg |
| EPY0000666 | Terazosin for system suitability | 0.5 mg |
| EPY0000622 | Terazosin impurity A 2-chloro-6,7-dimethoxyquinazolin-4-amine | 10 mg |
| EPY0000665 | Terazosin impurity E 2,2'-(piperazine-1,4-diyl)bis(6,7-dimethoxyquinazolin-4-amine) | 10 mg |
| EPY0000623 | Terazosin impurity L 1-(furan-2-ylcarbonyl)piperazine | 10 mg |
| EPY0000624 | Terazosin impurity N 1-[[[(2RS)-tetrahydrofuran-2-yl]carbonyl]piperazine | 10 mg |
| EPY0000535 | Terbinafine hydrochloride | 10 mg |
| New EPY0001143 | Terbinafine for system suitability | 10 mg |
| EPT0050000 | Terbutaline sulphate | 100 mg |
| EPT0050015 | Terbutaline impurity C 1-(3,5-dihydroxyphenyl)-2-[(1,1-dimethylethyl)amino]-ethanone | 15 mg |
| EPT0060000 | Terconazole | 250 mg |
| EPT0071000 | Terfenadine | 100 mg |
| EPT0080000 | Terfenadine impurity A 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl] butan-1-one (ketone) | 20 mg |
| EPT0100000 | Testosterone | 30 mg |
| EPT0200000 | Testosterone acetate | 10 mg |
| EPT0210000 | Testosterone caproate | 50 mg |
| EPT0240000 | Testosterone decanoate | 50 mg |
| EPY0000696 | Testosterone decanoate for system suitability | 0.4 mg |
| EPT0250000 | Testosterone enantate | 100 mg |
| EPY0000342 | Testosterone for impurity D identification | 15 mg |
| EPY0000343 | Testosterone for system suitability | 20 mg |
| EPT0260000 | Testosterone isocaproate | 50 mg |
| EPY0000716 | Testosterone isocaproate for system suitability | 5 mg |
| EPT0300000 | Testosterone propionate | 50 mg |
| EPY0000170 | Testosterone propionate - Reference Spectrum | unit |
| EPT0400000 | Tetanus vaccine (adsorbed) BRP | 11 mg |
| EPY0001087 | Tetra-O-acetyl-mannose triflate | 60 mg |
| EPT0500000 | Tetracaine hydrochloride | 100 mg |
| EPY0001002 | Tetracaine for system suitability | 2 mg |
| EPT0550000 | Tetracosactide | 2x0.366mg |
| EPT0600000 | Tetracycline hydrochloride | 100 mg |
| EPY0000015 | Tetrazepam - Reference Spectrum | unit |
| EPY0000008 | Tetrazepam impurity C 7-chloro-5-cyclohexyl-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one | 20 mg |
| EPY0000460 | Tetryzoline hydrochloride | 10 mg |
| EPY0000723 | Thebaine Controlled Substance | 10 mg |
| EPT0700000 | Theobromine | 100 mg |
| EPT0800000 | Theophylline | 100 mg |
| EPY0000294 | Theophylline - Reference Spectrum | unit |

European Pharmacopoeia

| Code | Product | Unit |
|------------|---|---------|
| EPY0000336 | Thiamazole | 125 mg |
| EPY0000372 | Thiamazol impurity A 2,2-dimethoxy-N-methylethanamine | 15 mg |
| EPY0000373 | Thiamazol impurity C 1-methyl-2-(methylsulphonyl)-1H-imidazole | 20 mg |
| EPY0000467 | Thiamine hydrochloride | 10 mg |
| EPY0000059 | Thiamine impurity E 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl) 4-methyl-4-thiazolidine-2-thione | 10 mg |
| EPY0000060 | Thiamine nitrate - Reference Spectrum | unit |
| EPT1100000 | Thiamphenicol | 125 mg |
| EPY0000546 | Thioctic acid | 110 mg |
| EPY0000592 | Thioctic acid for system suitability | 10 mg |
| EPY0000545 | Thioctic acid containing impurity B | 30 mg |
| EPY0000109 | Thiomersal | 30 mg |
| EPT1200000 | Thiopental | 500 mg |
| EPY0000704 | Thioridazine | 10 mg |
| EPT1300000 | Thioridazine hydrochloride | 100 mg |
| EPY0000541 | Thioridazine for system suitability | 0.21 mg |
| EPT1305100 | Thioxanthene | 20 mg |
| EPT1305000 | Thioxanthone | 10 mg |
| EPT1340000 | Threonine | 50 mg |
| EPT1350000 | Thymol | 50 mg |
| EPT1410000 | Tiabendazole | 50 mg |
| EPY0000414 | Tiamulin for peak identification | 10 mg |
| EPY0000333 | Tiamulin hydrogen fumarate | 450 mg |
| EPY0000379 | Tiamulin - Reference Spectrum | unit |
| EPY0000151 | Tianeptine sodium - Reference Spectrum | unit |
| EPY0000152 | Tianeptine for system suitability | 30 mg |
| EPY0000153 | Tianeptine impurity A ethyl 7-bromoheptanoate | 20 mg |
| EPT1405000 | Tiapride hydrochloride | 60 mg |
| EPT1405050 | Tiapride N-oxide | 20 mg |
| EPT1410900 | Tiaprofenic acid | 50 mg |
| EPT1410910 | Tiaprofenic acid impurity C (2RS)-2-(5-benzoylthiophen-3-yl)propanoic acid | 20 mg |
| EPY0000748 | Tibolone - Reference Spectrum | unit |
| EPY0000668 | Tibolone for system suitability | 10 mg |
| EPY0000465 | Ticarcillin monosodium | 250 mg |
| EPT1420010 | Ticarcillin impurity A (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[[(thiophen-3-yl)acetyl]-amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (decarboxyticarcillin) | 50 mg |
| EPT1423000 | Ticlopidine hydrochloride | 50 mg |
| EPT1423025 | Ticlopidine impurity F 6-(2-chlorobenzyl)4,5,6,7-tetrahydrothieno [3,2-c]pyridine | 10 mg |
| EPY0000325 | Tilidine hydrochloride hemihydrate - Reference Spectrum | unit |
| EPT1450000 | Timolol maleate | 50 mg |
| EPY0000644 | (R)-timolol | 20 mg |
| EPT1470000 | Tinidazole | 100 mg |
| EPY0000899 | Tinidazole impurity A 2-methyl-5-nitro-1H-imidazole | 10 mg |
| EPT1471000 | Tinidazole impurity B 1-(2-ethylsulphonylethyl)-2-methyl-4-nitroimidazole | 20 mg |
| EPT1490000 | Tinzaparin sodium | 250 mg |

| | Code | Product | Unit |
|------------|------------|---|---------|
| | EPY0000292 | Tioconazole - Reference Spectrum | unit |
| | EPY0000282 | Tioconazole for system suitability | 50 mg |
| New | EPY0001188 | Tiotropium bromide monohydrate | 10 mg |
| New | EPY0001216 | Tiotropium impurity F dithiophen-2-ylmethanone | 10 mg |
| New | EPY0001179 | Tiotropium impurity mixture | 0.08 mg |
| New | EPY0001189 | Tiotropium for system suitability | 10 mg |
| | EPT1500000 | Tobramycin | 51 mg |
| New | EPY0001210 | Tobramycin for identification | 250 mg |
| | EPY0000383 | All-rac-alpha-tocopherol for peak identification | 15 mg |
| | EPY0000384 | All-rac-alpha-tocopheryl acetate for peak identification | 15 mg |
| | EPT1550000 | alpha-Tocopherol | 250 mg |
| | EPT1600000 | alpha-Tocopheryl acetate | 250 mg |
| | EPT1610000 | RRR-alpha-Tocopheryl hydrogen succinate | 125 mg |
| | EPT1700000 | Tolbutamide | 100 mg |
| | EPY0000154 | Tolfenamic acid | 100 mg |
| | EPT1707000 | Tolnaftate | 60 mg |
| New | EPY0001123 | Tolnaftate for system suitability | 10 mg |
| | EPY0000461 | Torasemide anhydrous | 10 mg |
| | EPY0000462 | Torasemide for system suitability | 0.4 mg |
| | EPY0000155 | Tramadol hydrochloride | 75 mg |
| | EPY0000156 | Tramadol impurity A (1RS,2SR)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol | 15 mg |
| | EPY0000157 | Tramadol impurity E (2RS)-2-[(dimethylamino)methyl]cyclohexanone | 10 mg |
| | EPY0000072 | Tramazoline hydrochloride monohydrate | 20 mg |
| | EPY0000065 | Tramazoline impurity A N-(naphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine | 10 mg |
| | EPY0000066 | Tramazoline impurity B mixture of: 1-acetyl-2-[(5,6,7,8-tetrahydronaphthalen-1-yl)amino]-4,5-dihydro-1H-imidazole and N-(4,5-dihydro-1H-imidazol-2-yl)-N-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamide | 10 mg |
| | EPY0000501 | Trandolapril | 10 mg |
| | EPY0000495 | Trandolapril impurity C (2S,3aR,7aS)-1-[(2S)-2-[[[(1S)-3-cyclohexyl-1-(ethoxycarbonyl)propyl]amino]propanoyl]octahydro-1H-indole-2-carboxylic acid (hexahydrotrandolapril) | 10 mg |
| | EPY0000496 | Trandolapril impurity D ethyl (2S)-2-[(3S,5aS,9aR,10aS)-3-methyl-1,4-dioxodecahydropyrazino[1,2-a]indol-2(1H)-yl]- 4-phenylbutanoate (trandolapril diketopiperazine) | 10 mg |
| | EPT1810000 | Tranexamic acid | 50 mg |
| | EPT1820000 | Trapidil | 50 mg |
| | EPT1820002 | Trapidil impurity A 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol | 20 mg |
| | EPT1820004 | Trapidil impurity B 1,2,4-triazol-3-amine | 20 mg |
| New | EPY0001172 | Trehalose dihydrate | 250 mg |
| | EPT1850000 | Tretinoin | 50 mg |
| | EPT1899000 | 3,4,6-Tri-O-acetyl-D-glucal - Reference Spectrum | unit |
| | EPG0400010 | Triacetin - Reference Spectrum | unit |
| | EPT1899990 | Triamcinolone | 150 mg |
| | EPT1900000 | Triamcinolone acetonide | 100 mg |
| | EPT1950000 | Triamcinolone hexacetonide | 100 mg |
| | EPY0000050 | Triamcinolone impurity C 9-fluoro-11β-16α,17,21-tetrahydroxypregn-4-ene-3,20-dione | 10 mg |
| | EPY0000837 | Triamterene | 10 mg |

European Pharmacopoeia

| | Code | Product | Unit |
|------------|------------|--|-------------|
| | EPY0000870 | Triamterene impurity B 2,7-diamino-6-phenylpteridin-4-ol | 0.5 mg |
| | EPT1975000 | Triazolam Controlled Substance | 10 mg |
| | EPY0000165 | Tribenoside | 150 mg |
| | EPY0000166 | Tribenoside impurity A 3,5,6-tri-O-benzyl-1,2-O-(1-methylethylidene)- α -D-glucofuranose | 30 mg |
| | EPY0001055 | Tributyl acetylcitrate | 1 mL |
| | EPY0000279 | Tri-n-butyl phosphate | 300 μ L |
| New | EPY0000799 | Tributyl acetylcitrate for peak identification | 25 mg |
| | EPT1977990 | Tricaprin | 150 mg |
| | EPT1977995 | Tricaproin | 40 mg |
| | EPT1978000 | Tricaprylin | 225 mg |
| | EPY0000111 | Trichloroacetic acid - Reference Spectrum | unit |
| | EPT1985000 | Trichlorotrifluoroethane | 2.5 mL |
| | EPT1986000 | Triethyl citrate - Reference Spectrum | unit |
| | EPT2000000 | Trifluoperazine hydrochloride | 100 mg |
| | EPT2005000 | Triflusal | 50 mg |
| | EPT2005010 | Triflusal impurity B 2-hydroxy-4-(trifluoromethyl)benzoic acid | 25 mg |
| | EPY0000720 | Triglycerol diisostearate | 200 mg |
| | EPY0000108 | Trihexyphenidyl hydrochloride | 100 mg |
| | EPY0000068 | Trihexyphenidyl impurity A 1-phenyl-3-(piperidin-1-yl)propan-1-one | 20 mg |
| | EPT2009000 | Trilaurin | 1250 mg |
| | EPY0000092 | Trimetazidine dihydrochloride - Reference Spectrum | unit |
| | EPY0000093 | Trimetazidine for system suitability | 50 mg |
| | EPT2100000 | Trimethadione | 250 mg |
| | EPT2200000 | Trimethoprim | 50 mg |
| | EPY0000684 | Trimethoprim for system suitability | 0.00075 mg |
| | EPT2200010 | Trimethoprim impurity B (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone | 10 mg |
| | EPT2450000 | Trimethyltetradecylammonium bromide | 200 mg |
| | EPT2500000 | Trimipramine maleate | 100 mg |
| | EPY0000759 | Trimipramine for peak identification | 0.51 mg |
| | EPT2500100 | Trimyristin | 500 mg |
| | EPT2501200 | Tristearin | 100 mg |
| | EPT2545000 | Trolamine | 2250 mg |
| New | EPY0001184 | Trolamine impurity A Ethanolamine | 250 mg |
| New | EPY0001183 | Trolamine impurity B Diethanolamine | 1 mL |
| | EPT2550000 | Trometamol | 100 mg |
| | EPT2580000 | Tropicamide | 50 mg |
| | EPY0000616 | Tropisetron hydrochloride | 40 mg |
| | EPY0000618 | Tropisetron impurity B 1H-indole-3-carboxylic acid | 10 mg |
| | EPT2580300 | Tropine | 50 mg |
| | EPY0000429 | Trospium chloride | 10 mg |
| | EPY0000432 | Trospium impurity A Hydroxydiphenylacetic acid (benzilic acid) | 20 mg |
| | EPY0000431 | Trospium impurity B (1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl hydroxydiphenylacetate | 15 mg |
| | EPY0000430 | Trospium impurity C (1R,3r,5S)-3-hydroxy Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium] | 5 mg |

| Code | Product | Unit |
|-----------------------|---|----------|
| EPY0000497 | Troloxerutin | 30 mg |
| EPT2600000 | Trypsin BRP | 100 mg |
| EPT2610000 | Tryptophan | 100 mg |
| EPT2800000 | Tubocurarine chloride | 100 mg |
| EPT2880000 | Tylosin | 150 mg |
| EPT2880100 | Tylosin D | 5 mg |
| EPY0000498 | Tylosin phosphate for peak identification | 10 mg |
| EPT2880200 | Tylosin tartrate - Reference Spectrum | unit |
| EPT2900000 | Tyrosine | 50 mg |
| EPT3000000 | Tyrothricin | 10 mg |
| EPU0020000 | Ubidecarenone | 50 mg |
| EPU0020001 | Ubidecarenone for system suitability | 1 mg |
| EPU0020008 | Ubidecarenone impurity D 5,6-dimethoxy-3-methyl-2-[(all-E)-3,7,11,15,19,23,27,31,35- nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl] benzene-1,4-dione | 5 mg |
| EPU0100000 | Uracil arabinoside | 30 mg |
| EPU0600000 | Urea | 100 mg |
| EPU0800000 | Ursodeoxycholic acid | 60 mg |
| New EPY0001163 | Ursodeoxycholic acid for system suitability | 1.26 mg |
| EPY0000583 | Valerian standardised dry extract | 400 mg |
| EPV0030000 | Valine | 50 mg |
| EPY0000584 | Valnemulin hydrochloride | 10 mg |
| EPY0000533 | Valnemulin hydrogen tartrate | 120 mg |
| EPY0000585 | Valnemulin for peak identification | 20 mg |
| EPY0000586 | Valnemulin impurity E (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1-oxodecahydro- 3a,9-propano-3aH-cyclopenta[8]annulen-8-yl 2-hydroxyacetate (pleuromulin) | 10 mg |
| EPV0033000 | Valproic acid | 100 mg |
| New EPY0001132 | Valsartan | 10 mg |
| New EPY0001131 | Valsartan for peak identification | 10 mg |
| New EPY0001145 | Valsartan for system suitability | 0.202 mg |
| EPV0045000 | Vancomycin hydrochloride | 100 mg |
| EPV0050000 | Vanillin | 100 mg |
| New EPY0001198 | Varicella vaccine (live) | 420 mg |
| EPY0000561 | Vecuronium bromide | 10 mg |
| EPY0000625 | Vecuronium for peak identification | 10 mg |
| EPY0001093 | Vedaprofen | 5 mg |
| New EPY0001118 | Vedaprofen impurity mixture | 0.006 mg |
| EPY0000587 | Venlafaxine hydrochloride | 50 mg |
| EPY0000588 | Venlafaxine for system suitability | 1 mg |
| EPV0100000 | Verapamil hydrochloride | 100 mg |
| EPV0100018 | Verapamil impurity I (2RS)-2-(3,4-dimethoxyphenyl)-2-[2-[[2-(3,4-dimethoxyphenyl)- ethyl](methyl)amino]ethyl]3-methylbutanenitrile | 5 mg |
| EPV0100026 | Verapamil impurity M 5,5'-[[2-(3,4-dimethoxyphenyl)ethyl]imino]bis[2-(3,4-dimethoxyphenyl)- 2-(1-methylethyl)pentanenitrile | 10 mg |
| EPY0000661 | Verbenalin | 11 mg |
| EPV0180000 | VERO cells | 2x1 mL |
| EPV0200000 | Viscosimeter calibration liquids | 250 mL |
| EPV0300000 | Vinblastine sulphate | 5 mg |
| EPV0305000 | Vinblastine sulphate - Reference Spectrum | unit |

European Pharmacopoeia

| Code | Product | Unit |
|------------|---|---------|
| EPV0400000 | Vincristine sulphate | 4.98 mg |
| EPV0405000 | Vincristine sulphate - Reference Spectrum | unit |
| EPV0500000 | Vindesine sulphate | 5.11 mg |
| EPV0500010 | Vindesine sulphate - Reference Spectrum | unit |
| EPY0000463 | Vinorelbine tartrate | 50 mg |
| EPY0000464 | Vinorelbine impurity B 4-O-deacetylvinorelbine | 7 mg |
| EPY0000589 | Vinpocetine | 10 mg |
| EPY0000590 | Vinpocetine impurity A (12RS,13aSR,13bSR)-13a-ethyl-12-hydroxy-2,3,5,6, 12,13,13a,13b-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (ethyl vincamine) | 10 mg |
| EPY0000591 | Vinpocetine impurity B (13aS,13bS)-13a-ethyl-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (apovincamine) | 10 mg |
| EPY0000790 | Vinpocetine impurity C ethyl(13aS,13bS)-13a-ethyl-9-methoxy-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (methoxyvinpocetine) | 10 mg |
| EPY0000760 | Vinpocetine impurity D (12RS,13aRS,13bRS)-13a-ethyl-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (dihydrovinpocetine) | 10 mg |
| EPY0000793 | Vinyl acetate | 200 mg |
| EPW0100000 | Warfarin sodium | 100 mg |
| EPY0000778 | Warfarin sodium clathrate | 10 mg |
| EPX0075000 | Xylazine hydrochloride | 125 mg |
| EPY0000158 | Xylazine impurity C 2,6-dimethylphenyl isothiocyanate | 50 mg |
| EPY0000159 | Xylazine impurity E N-(2,6-dimethylphenyl)-S-methyldithiourea | 50 mg |
| EPY0001224 | Xylazine impurity mixture | 0.02 mg |
| EPX0080000 | Xylitol | 500 mg |
| EPX0100000 | Xylometazoline Hydrochloride | 100 mg |
| EPX0101000 | Xylometazoline impurity A N-(2-aminoethyl)-2-(4-1,1-dimethylethyl-2,6-dimethylphenyl)acetamide | 10 mg |
| EPX0200000 | Xylose | 100 mg |
| EPY0000656 | Yohimbine hydrochloride | 20 mg |
| EPZ1900000 | Zidovudine | 60 mg |
| EPZ1902000 | Zidovudine impurity A 1-[(2R,5S)-5-hydroxymethyl-2,5-dihydro-2-furyl]-5-methylpyrimidine-2,4(1H,3H)-dione | 10 mg |
| EPZ1904000 | Zidovudine impurity B 1-(3-chloro-2,3-dideoxy-β-D-ribofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione | 10 mg |
| EPZ2000000 | Zinc acexamate | 50 mg |
| EPZ2000010 | Zinc acexamate impurity A 6-[[6-(acetylamino)hexanoyl]amino] hexanoic acid | 50 mg |
| EPZ2500000 | Zolpidem tartrate Controlled Substance | 200 mg |
| EPZ2500010 | Zolpidem impurity A N,N'-dimethyl-2-[7-methyl-2-(4-methylphenyl)imidazol [1,2-a]pyridin-3-yl] acetamide | 10 mg |
| EPZ3000000 | Zopiclone Controlled Substance | 60 mg |
| EPZ3001000 | Zopiclone oxide | 20 mg |
| EPY0000062 | Zuclopenthixol decanoate - Reference Spectrum | unit |
| EPY0000534 | Zuclopenthixol for system suitability | 0.1 mg |
| EPY0000083 | Zuclopenthixol impurity B 2-chloro-9H-thioxanthen-9-one | 10 mg |